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OF BRCA1’S (BRCT) DOMAIN 
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Virginia Commonwealth University, 2013 
 
Advisor: Matthew C. T. Hartman, PhD, Department of Chemistry 
A growing body of literature suggests Breast Cancer-Associated Protein 1 (BRCA1) is 
important not only as a cause, but also as a target in the quest for cancer treatment.  BRCA1 
deficient cells treated with radiation as well as PARP inhibitors and other chemotherapeutics 
demonstrate a greater sensitivity than cells with wild type BRCA1.  Inhibitors of BRCA1 would 
take advantage of this synthetic lethality and represent a significant advance in cancer treatment 
as well as an understanding of the biology of DNA repair.  Despite significant study of BRCA1 
protein and function, it is a large protein (220 KDa) that is still largely uncharacterized, but its N- 
and C-terminal domains have been described by significant structural data.  The BRCT (BRCA1 
C-Terminal) Domain is a phosphoprotein binding domain that is commonly mutated or lost in 
cancers and has a binding cleft seemingly very suitable for drug design.  Small molecule screens 
have been conducted against this domain, but the resulting hits with moderate affinity have not 
been shown to induce BRCA1 deficient phenotypes.  Phosphopeptides have also been studied as 
potential BRCA1 inhibitors, yet despite some having affinities in the mid-nanomolar range the 
xi 
 
presence of a phosphate is not without its pharmacologic challenges.  We generated an mRNA 
display library with 1.3 x 10
13
 cyclized peptides covalently attached to the mRNA that encoded 
them.  Eight rounds of selection exposing the library to a GST-BRCT fusion resulted in selection 
of non-phosphorylated peptides that bind to a BRCT domain of BRCA1.  The sequences 
resulting from the selection have common homologies and initial characterization has shown that 
these peptides may be the first viable non-phosphoserine containing inhibitors of BRCA1.    
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CHAPTER 1. INTRODUCTION 
 
1.1 BRCA1 and Cancer 
1.1.1 BRCA1 Discovery  
The idea of a hereditary form of breast cancer was first put forth in a pedigree published 
in 1866,
1
 but it would be more than 100 years later until the discovery that this syndrome had a 
genetic basis in the form of a gene now known as the Breast Cancer Associated Protein 1 
(BRCA1).  After the initial Broca report in 1866, only a few similar familial studies were 
published over the next 100 years.
2
 It wasn’t until the 1960’s that Henry Lynch began collecting 
information from 120 families with hereditary breast and ovarian carcinomas creating the largest 
cohort of its kind in the world which came to be known as the Creighton families.
2
  Through 
genetic linkage studies in families with early-onset breast and ovarian carcinomas, King and 
coworkers who named the protein were able to identify the location of the responsible BRCA1 
gene to the long arm of chromosome 17.
3
  Applying this finding to the large sample size of the 
Creighton families, the location of BRCA1 on the chromosome was identified and the gene was 
cloned in 1994.
4
  Despite knowing the sequence of BRCA1 for nearly two decades, much of the 
structure of BRCA1 has yet to be fully elucidated, and the functions of this important gene are 
continuing to emerge.  
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1.1.2 A DNA Repair Protein with Many Functions 
BRCA1 is a large protein, weighing in at 220 kDa.
5
  Shuttling between the nucleus and 
cytoplasm, BRCA1 primarily acts as a scaffold protein forming many different complexes with 
other proteins to respond to many cellular functions and DNA damage. Many of BRCA1’s 1863 
amino acids have undetermined structure with the exception of the N-Terminal RING (Really 
Interesting New Gene) domain, C-terminal BRCT (BRCA1 C-Terminal) domain, and the coiled-
coil PALB2 (partner and localizer of BRCA2) binding domain.  The BRCA1 RING domain is 
constitutively bound to BARD1 as a heterodimer known as the core complex.  This complex is 
known to mediate E3 ubiquitin ligation.
6
  BRCT domains are found in many proteins that 
respond to DNA damage.   Many, but not all BRCT domains are phosphoprotein binding 
modules.
7
  The BRCT domain of BRCA1 is particularly important because of its many binding 
partners that interact at various times depending on their phosphorylation status.  The three major 
BRCT binding partners are Abraxas (also known as CCDC98 and FAm175A), BACH1 
(BRCA1-interacting protein C-terminal helicase 1, also known as FANJ and BRiP1), and CtIP 
(CtBP-interacting protein, also known as RBBP8).
8
  The complexes that form with these three 
proteins, BRCA1 as well as other associated proteins are named the BRCA1-A (Abraxas), -B 
(BACH1), and -C (CtIP). Together these complexes are known to regulate control of the G2–M 
checkpoint, BRCA1 accumulation at damage-induced foci, DNA replication, S-phase 
progression, DNA resection, and G2–M checkpoint control.9  The interaction of PALB2 and 
BRCA1 is known to be important to mediate homologous recombination (HR) repair of DNA, 
but this mechanism remains unclear.
9
  Other evolutionarily conserved sequences throughout the 
rest of BRCA1’s sequence imply that there are other important functions of this protein that have 
yet to be discovered.  Yet even with the small percentage of BRCA1 function currently known it 
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has still been dubbed the “master regulator of genomic integrity.”9  It is, therefore, no surprise 
that deficiency of this important protein can lead to a predisposition to cancer. 
 
1.1.3 The Role of BRCA1 in the Clinical Prognosis of Cancer 
For a very long time, a careful family history was the only means of determining ones 
risk for cancer.  In the 1990’s genetic linkage studies were applied to risk assessment for high 
risk families.
2
  Since then genetic counseling has progressed, and BRCA1 sequencing is now 
commonly applied for individuals at risk.  In addition non-sequence based BRCA1 deficiency 
tests, such as the protein truncation test were adopted quickly after the gene was identified.
10
  
Most BRCA1 testing is now done with direct gene sequencing, but the results of these tests are 
providing more questions than answers with respect to risk assessment and management.
11
 In 
addition to analysis of patient BRCA1 mutation carrier status, analysis of BRCA1 deficiency in 
individual tumors can have a significant impact on prognosis and treatment options.
12
   
 BRCA1 is a tumor suppressor gene (TSG), and its deficiency results in a whole host of 
cellular abnormalities.  This is why inherited homozygous deficiency is embryonic lethal, and 
why as a TSG under the two-hit hypothesis carriers of a single deficient copy of the gene are pre-
disposed to developing cancer.
13
  However, studies of patients with BRCA1 deficient tumors 
have revealed that they typically respond to DNA-damaging cancer therapies at a higher rate 
than do patients with tumors expressing wild-type BRCA1.
14
  In the past few years, researchers 
have begun discover the underlying mechanisms behind this observation, and have created new 
therapies to exploit these insights.  The most prevalent example of this are inhibitors of the 
enzyme poly ADP ribose polymerase (PARP).  PARP inhibitors (PARPi) prevent repair of 
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double-stranded DNA (dsDNA) breaks via the non-homologous end joining (NHEJ) pathway.
15
  
Because BRCA1 deficient cancer cells have aberrant homologous recombination repair (HRR) 
of dsDNA breaks, they therefore become more reliant on NHEJ to repair these breaks.
16
  The 
toxicity of PARPi on BRCA1 deficient cells is an example of synthetic lethality, and  PARPi are 
now being applied in the clinic as a much less toxic alternative to traditional cancer therapies in 
patients with BRCA1 deficiencies.
17
   
 
1.1.4 Need for Inhibitors of BRCA1 
From what has been learned from patients with BRCA1 deficient tumors, it is easy to see 
the implication that BRCA1 inhibitors could hold for cancer therapeutics.  Application of less-
toxic drugs such as PARPi with a targeted BRCA1 inhibitor could be applied to many different 
types of tumors regardless of BRCA1 status in order to mimic the BRCA1 deficiency that lends 
itself so nicely to synthetic lethality based treatments.  Another potential application for BRCA1 
inhibitors would be to prevent PARPi resistance.  Although tumors with BRCA1 mutations 
respond well to treatment with PARPi, they can become resistant to the treatment.
18
  Because 
tumors are heterogeneous and constantly evolving, it is no surprise that at least some of the cells 
express wild-type BRCA1, or acquire a mutation that results in reversion back to wild-type.  
Therefore combination of a PARPi or other therapeutics with a targeted BRCA1 inhibitor could 
help prevent this resistance and further improve cancer treatment in the high-risk BRCA1-
positive populations.  Additionally, despite the incredible amount of information that is known 
about BRCA1’s functions, it is central to a large web of cellular interactions that is still far from 
being untangled.  Site-specific, temporally controllable, and dosable inhibitors would be a 
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complementary and valuable tool in further understanding BRCA1 function leading eventually to 
better therapeutics not only for cancer but diseases that involve other BRCA1 related proteins 
such as Fanconi Anemia.
19
   
 
1.2 Peptides and Drug Development 
1.2.1 A Brief History of Drug Development 
 Surviving ancient texts from China, Egypt, India, Greece and Rome describe remedies 
for ailments of all sorts, but it was not until the 18
th
 century that medicine progressed from herbal 
remedies to seminal observations that became the birth of modern medicine.
20
  Jenner observed 
in 1796 that a patient exposed to cow pox was subsequently immune to small pox leading to 
development of the first vaccine.  Preventative medicine has certainly been revolutionized by 
vaccination, but arguably drugs have made an even larger impact on medicine.
21
  Advances in 
analytical chemistry lead to significant advances such as the isolation of morphine from opium in 
1815.
22
 However, at this time many of the foundations of chemical theory were still being 
formed, so pharmacology developed as a field in its own right.
21
  By the 1930’s natural product 
screening was the focus of drug development focused primarily on antibiotic discovery.
21
 
 In the 20
th
 century, biological observations combined with advances in chemistry lead to 
an explosion of efficacious drugs.  However, as of the late 1990’s only about 500 molecular 
targets were successfully targeted with drugs, and among these targets the majority were either 
cell-membrane receptors, G-protein-coupled receptors or enzymes.
23
  Despite advances in drug 
discovery techniques including combinatorial chemistry, and in silico based drug discovery, the 
number of new drugs reaching the market has dramatically diminished over the past 20 years to 
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the point where large companies develop only a single approved new chemical entity each 
year.
24
 The slowed productivity of the drug discovery pipeline has led to more interest in non-
traditional targets.  Among the promising new targets for drug discovery are protein-protein 
interactions (PPIs), despite their previous label of ‘un-druggable.’   
 
1.2.2 A New Role for Peptides in Drug Discovery 
Attempts to map the interactome have detected thousands of previously unknown PPIs 
and have only begun to brush the surface of this complicated network that governs the 
proteome.
25
  The reason these interactions have been overlooked for drug design is they are often 
flat and featureless
26
 and therefore not amenable to disruption by small molecules that have been 
so successfully applied to the classic biding pockets found in enzymes and many other proteins.  
More recent analysis of the surfaces of PPIs has shown that these surfaces are governed by more 
than hydrophobic interactions and often have longer binding grooves or a series of “hot spots” 
that combine to mediate the interaction.
26
  Despite this new perspective, PPIs often remain out of 
reach for inhibition with traditional small molecules.  This observation has led to attempts to 
inhibit these interactions instead through protein mimetics, such as peptides.
27
  With their larger 
size comes the ability to span the larger surface areas associated with PPIs which can often lead 
to greater specificity than generally found with small molecule drugs.  Despite the great potential 
of peptides to act as inhibitors to a wealth of new drug targets in the form of PPIs, the idea of 
such approaches has been met which much skepticism. 
The criticism of peptides as drugs is due primarily to their inherent susceptibility to 
protease degradation and lack of inherent cellular permeability, which would make them unlikely 
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drug candidates in the traditional sense.  However, there are a surprising number of peptides and 
peptide-derivatives found on the market today and many tools are being developed to overcome 
remaining challenges.
28
  Many of these peptides mostly bind to extra-cellular targets, but with an 
ever increasing number of methods for intracellular peptide delivery (such as CPPs,
29
 pHLIP,
30
 
lipid
31
 and nano-particle
32
 based delivery systems), peptides are becoming even more viable 
drugs to target PPIs.  The issue of stability has been addressed in many simple ways including 
the synthesis of retro-inverso, N-methylated, and stapled peptides.  In fact recently a stapled 
peptide entered human trials for the first time.
33
  Although peptide drugs still have several 
obstacles to overcome, they are emerging as a very promising new class of drugs for a vast pool 
of untapped drug targets.  
 
1.3 Current Development of BRCA1 Inhibitors 
1.3.1 Introduction 
The radio- and chemo-sensitive phenotype associated with BRCA1 deficiency points to 
inhibition of BRCA1 as a potential therapeutic strategy. However, most of BRCA1’s functions 
are mediated by protein-protein interactions (PPIs).
9
 Historically, achieving PPI inhibition has 
been challenging due to the fact that the contact surface of PPIs is often little more than a flat, 
large surface void of suitable binding pockets for small molecules.
34
  However, an increased 
interest in PPIs, and the development of intermediate-sized therapeutic agents capable of binding 
to large surfaces, has made the inhibition of some PPIs a therapeutically attractive strategy.
35
  
The complete structure of BRCA1 (see Figure 1.1) has yet to be determined, but the crystal  
8 
 
 
Figure 1.1 Potential BRCA1 Therapeutic Targets. BRCA1 with its RING, tandem BRCT, 
and overlapping SQ cluster and coiled-coil domains are indicated. Although the BRCT domain 
and, to a lesser extent, the RING domain, have been the focus of inhibitor design, others such 
as the coiled-coil domain may also be viable targets. The Zn2+binding sites of the RING 
domain can be non-specifically inhibited by platinum compounds listed here in order of their 
affinity for the domain.48 Extensive exploration of phosphopeptides that bind to the BRCT 
domain has resulted in the peptide shown which has a Ki of 40 nM.
47a Structural 
representations are of the BRCA1 RING and BRCT domains co-crystallized with the RING 
domain of BARD1 and a BACH1 phosphopeptide, respectively, and were adapted from PDB 
entry codes 1JM749 and 1T29,50 using the PyMOL Molecular Graphics System (Schrödinger, 
LLC).
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structures of the N-terminal RING and C-terminal tandem BRCT domains are available to guide 
inhibitor development.
36
 
 
1.3.2 N-terminal RING Domain 
The BRCA1 RING domain is composed of a Zn
2+
 binding region of 8 Cys and His 
residues that form two separate Zn
2+
 binding sites and an adjacent coiled coil region.
37 
This 
domain is known to interact primarily with BARD1, forming a heterodimer that possesses E3 
ubiquitin ligase activity. Mutations that result in the loss of BRCA1 ubiquitin ligase activity, 
mainly due to the disruption of BARD1 binding,
38
 render cells sensitive to ionizing radiation.
39
 
Until recently, the BRCA1-BARD1 complex was thought to be constitutive. However, it was 
recently demonstrated that when BRCA1-BARD1 binds to p53 in the nucleus, BARD1 
dissociates, leading to the export of BRCA1 to the cytoplasm and concomitant sensitization of 
cells to DNA damage.
40
 Therefore, inhibitors of BRCA1 and BARD1 interaction should lead to 
radio- and chemo-sensitization. The binding surface between BRCA1 and BARD1 is primarily 
composed of a 4-helical bundle, with two helices contributed by each protein. The interface is 
quite large (2,200 Å
2
), and presents a formidable challenge for disruption. There is, however, 
some precedent for disruption of helical bundles. For example, the HIV protein gp41 assembles 
into a six helical bundle that is disrupted effectively with peptides, including the HIV drug 
Fuzeon.
41
 Interestingly, most cancer-predisposing mutations in the BRCA1 RING domain occur 
not in the interface between BRCA1 and BARD1, but in the Zn
2+
 binding sites of the RING 
domain.
39b, 42
 Platinum based anticancer drugs have previously been shown to preferentially bind 
to Zn
2+
 finger domains, replacing Zn
2+
 and thereby altering the protein tertiary structure.
43
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Recently, it was shown in vitro that platinum agents, shown in Figure 1.1, are able to bind to the 
RING domain and inhibit its E3 ubiquitin-ligase activity by ejecting Zn
2+
.
42
 The Zn-ligating 
residue H117 of BRCA1 was demonstrated to be the primary platinum binding residue.
44
 Further 
work is required to develop specificity for BRCA1 prior to implementing this strategy in living 
cells.  
 
1.3.3 C-terminal BRCT Domain 
The BRCA1 tandem BRCT domain is a member of a family of BRCT motifs known to bind 
phosphorylated proteins involved in DNA repair as well as having other functions.
7a, 45
 
Sometimes these domains exist as a single motif, but often they are found in series, as is the case 
with BRCA1. Mutations in this domain are among the most common BRCA1 mutations in 
hereditary breast cancer.
36a
 The BRCT domain has potential for inhibitor development due to its 
well-defined, relatively small binding cleft known to interact with proteins having pS-X-X-F 
motifs.
7a, 36a, 36c
 Early work using SPOT peptide libraries identified the preferred binding 
sequence as phospho-Ser-aromatic β-branched/aromatic-Phe and confirmed that the phospho-Ser 
and Phe are the primary requirements for binding.
7, 46
 The highest affinity peptide from this 
screen had an affinity of 162 nM. 
Recently, a high-throughput assay based on fluorescence polarization to identify small 
molecules that bind to the BRCA1 BRCT domain was developed.
47
 An initial screen of the NCI 
diversity database led to a single hit with an IC50 of 10 μM. Later, a dual fluorescence screen of 
75,000 compounds identified 16 inhibitors with the lowest IC50 values in the single digit 
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micromolar range. However, some of these compounds have intrinsic fluorescence or act as 
fluorescence quenchers, suggesting, as the authors acknowledge, that they may be false positives.   
Further optimization of peptide inhibitors by Natarajan and coworkers led to a 
tetrapeptide, whose structure is shown in Figure 1.1, with a 40 nM binding affinity.
48
  Despite the 
challenges of drug delivery and cellular stability due to the phosphoserine, one report does exist 
showing that a phospopeptide is capable of inhibiting BRCA1 in cellular studies.
49
  These studies 
required very high concentrations of drug (100 µM), and were examined only after very short 
time periods of drug exposure.  With these limitations combined with the fact that the inhibitory 
results were small and far from clinically significant, it is unlikely that continuing to develop 
phosphate-based drugs for BRCA1 inhibition will be successful.  Thus, therapeutically useful 
BRCA1 BRCT inhibitors remain elusive.  
 
1.3.4 PALB2 and SQ Domains 
At present, little is known about the BRCA1 structure outside of its two terminal domains. Much 
of the internal region of BRCA1 contains evolutionarily conserved sequences, but their function 
remains to be fully determined.
9
 There is, however, the SQ cluster (amino acid residues 1,241–
1,530) with a number of S-Q residues phosphorylated by ATM and ATR.
50
 These regions 
constitute “non-druggable” BRCA1 targets except indirectly by inhibiting these kinases. 
Elucidating how the phosphorylation of this internal domain affects the activities of the N- and 
C-terminal domains is still an underexplored area, yet is critical to the design of BRCA1-based 
therapeutics targeting this region. In addition, the coiled-coil domain (amino acid residues 
1,364–1,437) encompassed by the SQ cluster was shown to interact with PALB2 which, in turn, 
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associates with BRCA2.
51
 Phosphorylation of S-Q residues within the SQ cluster was shown not 
to affect PALB2 binding.
51b
 However, the disruption of this interaction by cancer patient-derived 
BRCA1 mutations lead to decreased HR and mitomycin C hypersensitivity,
51a
 making it an 
interesting target from a therapeutic standpoint. To block the interaction of BRCA1 and PALB2, 
one approach could be the use of hydrocarbon-stapled peptides, which have been shown to 
disrupt protein-protein interactions involving helical interfaces.
52
   
 
1.4 Peptide Selection with Libraries 
1.4.1 Peptide Libraries: An Introduction 
It is clear that BRCA1 is an important drug target, but it is a difficult target if viewed 
through a lens of traditional drug design.  This is because its functions are mediated by protein-
protein interactions, but somewhat non-traditional drugs such as peptides are ideally suited for 
the challenge.  Much progress has been made in the rational design of peptide drugs, yet despite 
more advanced algorithms and increased computing power,
53
 examples of high affinity peptide 
drugs from rational design are still rare.
54
 Therefore, scientists have turned to powerful strategies 
for the creation of diverse peptide libraries using “molecular evolution” or “irrational design.”55  
In addition to other advantage of peptides as drugs, small molecule screened as potential drugs 
are limited by the amount of time it takes to synthesize each unique library member, as well as 
the often laborious task of screening each member individually.  Unlike small molecules, a wide 
variety of peptides can by synthesized relatively easily simply by changing the order of amino 
acid addition.  Even the smallest peptide libraries far outreach the capacity of high-throughput 
screening techniques, and with the ability to easily generate a vast number of peptide members in 
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a library, it would be far too daunting a task to screen each library member individually.
56
 
Fortunately peptides have been very amenable to many different types of selections where an 
entire library is screened simultaneously against a single target thus dramatically reducing the 
time to identify lead sequences.   
1.4.2. Immobilized Peptide Libraries (SPOT and OBOC) 
Since the 1990s “spot synthesis” of peptides has emerged as a facile way to prepare and 
screen a large number of peptides against a desired target.
57
  Unlike small molecule screening, a 
diverse library can easily be synthesized including incorporation of unnatural amino acids, and 
due to its immobilization onto solid support the sequence of each peptide is known by its 
location.  Screening of a target protein against such a peptide array makes sequencing 
unnecessary for identification of lead peptides.  The need to detect bound proteins is one 
disadvantage of this technique.  Labeling of the protein with a fluorescent tag can lead to 
changes in protein properties and solubility, and secondary detection with antibodies can lead to 
false positives via non-specific interaction with peptides.
58
  Additionally, even with advances in 
photo lithography a single micro-array contains only 768 members, which limits its power in the 
drug discovery process.
58
  
Another method of generating a large peptide library on solid support is known as the 
“split and mix” method used in the “one bead one compound” (OBOC) approach developed in 
the late 1990s.
59
  Instead of synthesizing peptides on known locations of a membrane support, 
this technique utilizes resin that is split apart before each amino acid addition then recombined 
and split again before the next addition.  This results in the synthesis of a diverse library with a 
decreased number of chemical reactions.
60
  This technique allows for the incorporation of 
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unnatural amino acids, which allows for the creation of a more “drug-like” library. Screening is 
often done via on bead binding with detection of bound proteins either by fluorescent probes 
fused to the protein or to an antibody.
61
  Careful selection of resin also allows the application of 
flow cytometry for automated counting, which increases the speed of screening.
62
  Fluorescence 
is proportional to the binding affinity, so leads are easily identified, but sequencing is reliant 
upon either Edman degradation or MS/MS sequencing, which can be challenging to perform.  
However, with the ability to screen 10
7
 to 10
8
 beads/compounds in only a few hours or less, it is 
easy to see the power of this technique.   
 
1.4.3 Cellular Display Techniques: Phage and Cell Based Display 
Although chemical synthesis of peptides has significantly improved since Emil Fisher’s 
initial work in the 1930’s,63 chemical synthesis of peptides is still a highly inefficient process 
when compared to the power of ribosomal translation.
64
  Libraries created through expression of 
peptide variants as surface displayed protein fusions have the dual advantages of easy 
“synthesis,” and easy sequencing.  Because each peptide library member is generated via 
translation, it is inherently linked to a cDNA sequence that can be PCR amplified and sequenced 
via routine methods allowing easy identification of library members that bind to the desired 
immobilized target. The library size for cell-based libraries is dependent upon transformation 
efficiency, and with recent advances can reach up to 10
10
 members in size,
65
 but library sizes are 
more commonly around 10
8
-10
9
.
66
   
Although cell based displays may provide a means to create larger libraries, they do not 
allow for efficient incorporation of unnatural amino acids.  Although some labs have the ability 
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to incorporate one or two non-natural amino acids via amber and opal codon suppression as well 
as other orthogonal genetic incorporations,
67
 these techniques are limited and not in wide use.  
Phage display has become the most widely used of the cell based peptide libraries due in part to 
its small particle size in selection, which allows for a smaller host surface to interfere via non-
specific target binding compared to the size of a yeast or bacterial cell.
68
  The close proximity of 
peptides displayed on a phage surface can lead to avidity effects where peptides bind 
cooperatively to generate a net high affinity.  This is a disadvantage, as it complicates correlation 
of phage-displayed and synthesized peptide affinities.   
 
1.4.4 In vitro Display Techniques: mRNA and Ribosome Display 
Although the term display was originally used to describe the display of peptides on the surface 
of a host, it has come to be synonymous with library technologies that are genetically encoded. 
Each display technique shares the advantage that even a single peptide surviving a selection can 
have its sequence determined or amplified from its associated code.  For bacteria, yeast and 
phage display this code or template of the peptide sequence is cDNA; however, as techniques to 
work with mRNA have improved, mRNA itself has become a viable purveyor of genotype 
directly, such that maintaining cDNA is not necessary to link genotype to phenotype.  Using 
mRNA to determine peptide sequence requires reverse transcription followed by PCR 
amplification, but it has allowed peptide libraries to be created via cell free systems. 
Ribosome Display.  In Ribosome display the attachment of the mRNA template and translated 
peptide is mediated by the ribosome itself (See Figure 1.2).  The mRNA is designed such that the 
code for the peptide library is followed by a spacer sequence and does not end in a stop codon  
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Figure 1.2 mRNA Display and Ribosome Display. mRNA display and ribosome display are 
two methods of generating ribosomaly transcribed peptide libraries in vitro. B) With ribosome 
display, the ribosome, mRNA and peptide remain non-covalently attached with a spacer filling 
the ribosomal tunnel, so that the library peptide can be “displayed” on the ribosome. A) In 
mRNA display, after the ribosome translates the mRNA template into peptide, it stalls at the 
double stranded region of the template allowing puromycin (P) to enter into the A site and 
form a covalent bond with the peptide forming a genetic link of genotype and phenotype.
A. mRNA Display
B. Ribosome Display
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which results in a persistent mRNA-ribosome-peptide complex.  The spacer sequence is 
necessary so that the peptide chain can be long enough to exit the ribosomal tunnel and therefore 
is “displayed” during selection.  The translation reaction is only 5-10 minutes, and after the 
reaction is quenched it must be kept at cold temperature (4 °C) throughout the selection.
69
   One 
drawback of this technique stems from the fact that this complex is non-covalent in nature and 
therefore selection with ribosome display must be carefully conducted in vitro to preserve the 
fragile mRNA-ribosome-peptide complex.   
mRNA display.  The mRNA-peptide fusion formed during mRNA display overcomes fragile 
nature of ribosome display by creating a covalent linkage between the mRNA and peptide thus 
eliminating the need for the ribosome to persist in the complex (See Figure 1.2).  This is 
accomplished with an mRNA lacking a stop codon which is replaced with an extended region 
that is complementary to a DNA oligo that acts as a linker for attachment of puromycin.
70
  After 
annealing of the mRNA and DNA, UV crosslinking or splinted ligation forms a covalent 
attachment between them.  Puromycin is an antibiotic that acts by inhibiting translation.
71
  The 
slow kinetics of puromycin allow translation to continue at a normal rate without interruption; 
however, when the ribosome stalls due to lack of a stop signal at the juncture of double stranded 
mRNA/DNA the puromycin has time to enter the A site of the ribosome.
72
  Once puromycin 
enters the A site, the ribosome catalyzes an amide bond between it and the C-terminal end of the 
peptide, thus creating a covalent linkage between the mRNA and the single peptide it encoded.  
This more stable structure allows a variety of selection conditions with no need to worry about 
mRNA and peptide dissociation.   
 Once this mRNA/peptide fusion has been generated, in reality there are two aptamer 
libraries: one of RNA and one of peptide.  Because RNAs themselves can bind to a variety of 
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targets, the reverse transcription that would be necessary for eventual PCR is conducted prior to 
selection so that the RNA is more like a “featureless” negatively charged rod rather than a 
molecule with unique secondary structure which could interfere with selection.  Because neither 
ribosome nor mRNA display are limited by transformation efficiency, libraries up to >10
15
 have 
been generated.
73
  In selection, diversity is very important, and a library of this diversity adds 
great power to these techniques.
74
 Additionally being in a cell-free system allows more control 
and when conducted as a PURE translation system, UNAAs can easily be incorporated by 
substitution rather than cumbersome bio-orthogonal methods.
75
   
 
1.4.5 Incorporation of Unnatural Amino Acids in Translation 
 The ability to incorporate UNAAs into proteins or peptides via the translational 
machinery offers many beneﬁts.76 For example, the ability to directly incorporate unnatural 
amino acids affords direct and simple access to functional groups generally only found in post-
translationally modiﬁed proteins.77 Similarly, the ability to site-speciﬁcally label proteins with 
unique functional groups not found in the standard proteinogenic AAs has enabled new means to 
control protein function inside cells.
78
 For peptides, the incorporation of UNAAs can lead to 
enhanced stability and permeability, problems that have traditionally hindered the development 
of peptides as therapeutics.
79
 For instance, peptides that contain even a single N-methyl amino 
acid can show enhanced bioavailability and protease stability.
80
 A chief reason to pursue 
translational incorporation of UNAAs into peptides is that it in theory expands the chemical 
diversity of the already extremely diverse (>10
13
-member) drug-like peptide libraries using 
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techniques like mRNA display.
71-72
 This ability to create these libraries hinges on the 
development of methods to deliver UNAAs into the translation apparatus.  
The ﬁrst step for the introduction of UNAAs using in vitro translation is their ligation 
onto tRNAs. There are several strategies to achieve formation of non-natural aminoacyl-tRNAs. 
The original approach involved chemical attachment of the UNAA onto a dinucleotide followed 
by enzymatic ligation onto a truncated tRNA.
67a, 81
 These chemically charged tRNAs could then 
be used with in vitro translation reactions.
82
 This strategy has now been extended so that instead 
of chemically charging individual tRNAs, a whole family of orthogonal aminoacyl-tRNA 
synthetase/suppressor tRNA pairs that can be used to incorporate UNAAs site specifically in 
vivo.
83
 An alternative strategy involves charging of a proteinogenic amino acid onto a tRNA, 
followed by converting it into an UNAA while attached to the tRNA. For example, reductive 
amination can convert a proteinogenic aminoacyl-tRNA into its N-methylated form. This 
approach can be used to synthesize peptides containing N-methylated backbones.
84
 Finally, 
Suga, using an RNA catalyst, has developed a means to charge virtually any UNAA ester onto 
tRNAs. In their method, an artiﬁcial, ﬂexible ribozyme, called ﬂexizyme, recognizes the 3’ end 
of the tRNA in conjunction with benzylic esters of amino acids and charges the amino acid to the 
tRNA.
85
  Four different leaving groups have been developed that can be used to functionalize 
essentially any amino acid.
86
  These leaving groups are recognized by three different flexizymes 
hypothetically allowing any amino acid to be mischarged onto a tRNA and therefore 
incorporated into translation products.
86
  This general strategy has been applied for the 
incorporation of many UNAAs into peptides.
87
 
Surprisingly, the wild-type aminoacyl-tRNA synthetases are able to charge a wide variety 
of unnatural amino acids onto tRNAs.
88
 This ability suggests that such laborious engineering 
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approaches may not be necessary because incorporation of an UNAA would only require adding 
it to an in vitro translation reaction in place of its natural amino acid counterpart. While 
conceptually simple, standard cell extracts are highly contaminated with natural AAs, precluding 
this strategy. The reconstituted PURE (protein synthesis using recombinant elements) translation 
system
89
 solves this problem because the natural amino acids can be withheld from translation. 
Thus the PURE system components can be tailored such that UNAAs are substituted for natural 
amino acids.  
 
1.4.6 Unnatural Peptide Library Selections  
 Directed evolution and library selections have no doubt had significant impact on 
biology,
90
 but there have been many fewer selections conducted with UNAAs present in the 
library.   There have however, been several selections performed with UNAAs, that were 
successful in producing peptides that bind to various targets with drug-like modifications through 
UNAA incorporation.
91
  One selection is of particular interest because it conducted as two 
parallel selections against thrombin, one with only natural amino acids and a second with an 
UNAA complement.
92
  Although in this case, the UNAA peptides selected did not have higher 
affinities than the natural peptides selected (both had low nM affinities), they did in fact discover 
completely unique binding motifs that no longer bound to the target upon natural amino acid 
reversion.  UNNA containing peptides such as these are more promising drug candidates from 
the outset because of their non-native structures.     
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1.5 Characterization of Binding Affinities 
1.5.1 What is a Binding Affinity?  
The term “binding affinity” is a general term used most commonly to refer to the 
equilibrium dissociation constant (Kd).  For the simple reaction A + B → AB, a mathematical 
description of this constant would be the ratio of the concentration of A and B to the complex 
AB at equilibrium (Equation 1, concentrations are denoted in square brackets).   
(1)   
[ ][ ]
[  ]
 
The Kinetic description of the dissociation constant is a ratio of measured on and off rates of 
binding (Equation 2, koff = off-rate, kon = on-rate).  
(2)   
    
   
 
Thermodynamic analysis of a binding interaction is described in terms of Gibbs free energy (ΔG) 
(Equation 3, R = gas constant, T = temperature). 
(3)     
 
         
 
The Kd of a molecular interaction can be measured through many different types of methods, 
many of which provide little description of the molecular details of how the molecules interact.  
However, there are other techniques that provide access to Kd through kinetic and 
thermodynamic measurements.  These measurements provide additional molecular details that 
are important for guiding drug design.  The strengths and weaknesses of several techniques for 
measuring the Kd are reviewed in the following sections.  
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1.5.2 Equilibrium Ultrafiltration Binding Assay 
Many different methods have been developed to study the binding affinities of molecules.
93
  
Among the simplest of these techniques from a theoretical and application stand point is the 
radio-ligand spin assay.
94
  As the name might imply, this technique requires radiolabeling of the 
ligand of interest.  In the study of a peptide-protein interaction, this could easily be achieved via 
incorporation of 
35
S-Met into the peptides’ structure.  A typical experiment, as shown in Figure 
1.3, combines this radio-labeled peptide at constant concentration in multiple samples containing 
varying concentration of the protein of interest.  After incubation to allow for the peptide to 
equilibrate between being free in solution and bound, the sample is placed into a spin filter with a 
membrane with specific molecular weight cut off such that the protein will remain in the upper 
portion of the spin filter and the unbound peptide will be evenly dispersed in both the sample 
remaining in the top portion of the spin filter and the flow through. Scintillation counting of the 
two separated solutions allows for mathematical determination of the fraction of radio-labeled 
peptide bound to the protein.  Equation 4 holds when the volumes above and below the filter are 
identical after centrifugation.  From a sigmoidal plot of fraction bound verses protein 
concentration, the Kd can be calculated as the inflection point of the graph where 50% of the 
protein binding sites are occupied. 
(4)   
[             ]
[             ]
 
[          ]
[   ]
 
 
These assays are technically challenging to perform because slight variations in the volume that 
passes through the membrane will skew the results.  In addition the data obtained is not as 
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Figure 1.3 Equilibrium Ultrafiltration Binding Assay. Various concentrations of  
protein are added to a constant concentration of 35S-labeled peptide.  After 
incubation, the samples are centrifuged in 30,000 MWCO filters until the sample is 
divided, half filtered through the membrane, and half remaining in the top.  A fraction 
bound (FB) can be calculated for each sample and then plotted to achieve a binding 
curve.   
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 precise as many of the other techniques to determine binding affinity. Due to the sensitivity 
provided by monitoring binding with scintillation counting, only a small amount of radiolabelled 
peptide is need, such that peptides prepared on in vitro translation scale using 
35
S methionine 
incorporation are more than sufficient. 
Being the conceptually simplest techniques, as one might expect a radio-ligand spin assay 
does not require particularly expensive or sophisticated equipment.  The primary hurdle to these 
assays is access to radio-labeled ligands.  With radio-labeled spin assays reproducibility can be 
challenging.  Although, this can be mathematically corrected in theory, in actual practice this is 
not a highly precise technique.   
 
1.5.3 Isothermal Titration Calorimetry (ITC) 
Rudimentary calorimetry qualitatively comparing the “heat of a breeding hen” and the 
“head of boiling water” dates back to the 17th century even before the invention of the first 
thermometer.
95
  Since many biological interactions are accompanied by changes in heat, through 
the years calorimetry has become an increasingly useful tool.  By the mid-20
th
 century, 
calorimeter design had advanced significantly; however, it hasn’t been until the past 20-30 years 
that advances have been significant enough to results in affordable, easy to use, stable, and 
sensitive enough to result in routine thermodynamic analysis of biological interactions.
95
  
Modern “microcalorimeters” require as little as 10 nanomoles of sample in a volume of as little 
as 200µL. 
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Isothermal Titration Calorimetry (ITC) is the modern form of Calorimetry used in 
laboratories to measure biological interactions.  The instrument is composed of a reference 
chamber, containing water or a buffer, and sample chamber as shown in Figure 1.4.  Both  
chambers are kept at a constant temperature (isothermal), and the sample chamber is fitted with a 
long syringe with a paddle-like end that rotates in order to stir the sample.  Known quantities of 
the ligand are titrated into the sample chamber, and the heat of the interaction between 
macromolecule and ligand is indirectly measured after each injection.  Because the instrument 
maintains a constant temperature, the measurement is the amount of power (microcalories per 
second) supplied to the reference or sample chambers in order to maintain a constant 
temperature.  In the case of an exothermic reaction more power would be needed for the  
reference chamber, and for an endothermic reaction more power would need to be supplied to the 
sample chamber to maintain a constant temperature.   
Figure 1.5 shows a typical ITC curve of an exothermic reaction.  The area under each peak 
corresponds indirectly to the amount of heat change (ΔH) occurring as a result of each injection, 
with a return to baseline occurring in between each injection.  As progressively more ligand is 
added, the free protein concentration decreases resulting in progressively smaller peak magnitude 
and eventual saturation.  An ideal curve is sigmoidal.  The inflection point gives the 
stoichiometry (N) of binding, and the binding constant (K) is most often determined from a  
“single site binding constant” model.96  Thus ITC directly gives N, K and ΔH, from which ΔG 
and ΔS can be calculated given Equations 5 and 6. 
 
(5)           
(6)           
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Sample Chamber Reference Chamber
Peptide in Syringe
Protein in Chamber
Figure 1.4 Setup of an Isothermal Titration Instrumentation. Consisting of two 
chambers kept at the same temperature, the reference chamber is filled with buffer 
or water.  As peptide (or other ligand) is titrated into the protein in the cell, the 
current change needed to keep the chambers at a constant concentration is 
measured.  As more peptide is added and the interaction saturates, a binding 
isotherm is obtained, as seen in Figure 1.5.
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Figure 1.5 An Example ITC Isotherm.  As aliquots of peptide are added over 
time the sample chamber containing protein, the heat released for the binding 
events is indirectly measured in µcal/sec.  The “heat release” dissipates as binding 
sites are exhausted, and a binding curve is observed.  
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ITC is the only technique that gives the magnitude of the two thermodynamic values of ΔH 
and ΔS.  This can be a very powerful tool in guiding drug design because thermodynamic  
properties are important for the elucidation of binding mechanisms.  Despite this strength, ITC 
has its limitations.  The biggest of these is governed by the constant c, which is expressed in 
equation 7,  
 
(7) c =n[M]TK 
 
where n is the number of binding sites, [M]T is the total macromolecule (usually protein) 
concentration), and K is the equilibrium binding constant.
18
  Sigmoidal curves generally are 
observed when c is between 10 and 100.
97
 A c value that is too low will have a flat curve that 
gives little information about binding affinity or stoichiometry.  However, a c value that is too 
high creates a steep, sigmoidal curve that cannot be accurately interpreted.  Given that n and K 
are inherent to the binding interaction under study, the only means of manipulating the c value is 
to change the concentration of protein in the chamber.  Protein solubility and aggregation 
typically limit the ability to compensate for low c values with high protein concentrations, while 
the sensitivity of ITC limits the ability to use a low protein concentration to compensate for high 
c values.  If a fixed protein concentration of 20 µM is assumed in a reaction with 1:1 
stoichimetry, ITC is typically limited to measurements of Kds in the range of 2 µM to 200 nM.   
ITC is the gold standard of binding affinity measurement because it allows for tag-free 
analysis of molecules and study of interactions in thermodynamic detail.  This makes it a very 
powerful technique because a single experiment can determine all the major thermodynamic 
constants of an interaction; however, the high level of calorimeter needed to measure the small 
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heats of binding during a titration is quite expensive.  After the initial purchase price, the 
cleaning and maintenance of these instruments is quite intensive, and can lead to inaccurate data 
if not maintained properly.  Additionally even the new microcalorimeters require a fairly large 
amount of material, especially when compared to fluorescence polarization experiments that can 
be adapted to 384 well plates. When combined with an approximately 2 hour experiment time 
and the need to run a blank for every sample, it becomes clear to see that this technique is not 
adaptable to high-throughput screening.  
 
1.5.4 Fluorescence Polarization (FP) 
Also known as Fluorescence Anisotropy, this technique takes advantage of differing tumbling 
rates of molecules of varying mass in solution. In 1920 F. Weigert discovered that excitation of 
fluorescent dyes with polarized light resulted in emission of polarized light.
98
  Additionally he 
observed that the degree of polarization observed in the emitted light was inversely proportional 
to the size of the dye measured.  This is to say that smaller molecules that are tumbling faster in 
solution “scramble” the light so the emitted light is less polarized, and that larger molecules that 
tumble slower maintain more polarity in the emitted spectrum (see Figure 1.6). As complexes 
form, naturally the mass increases, which makes FP a suitable technique for studying binding 
interactions.  In designing an experiment, ideally the fluorophore would be appended to the 
smaller of the two molecules under study because this would provide a larger difference in 
anisotropy upon binding; however, attaching a large fluorophore to the smaller molecule is more 
likely to alter the interaction of the two molecules under study.    Polarization and Anisotropy 
measurements are described mathematically in equations 8 and 9,  
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Polarized 
Light
Depolarized 
Light
Largely 
Polarized 
Light
Polarized 
Light
Less 
Polarized 
Light
Figure 1.6 Fluorescence Polarization. FP analysis takes advantage of the fact that certain 
fluorophores emit polarized light when excited with polarized light. When smaller molecules, 
like peptides, are excited with polarized light their quick tumbling in solution scrambles the 
emitted polarized light.  When such a labeled peptide binds to a protein, the rate of tumbling 
slows and more polarized light is observed.  In a competition assay, a competing peptide 
(shown in orange) competes off the fluorescently labeled peptide resulting in the observation of 
less polarized (more scrambled) light emitted.  
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(8)   
         
         
 
(9)   
         
            
 
  
   
 
where P is polarization, r is anisotropy, and the intensity of fluorescent readings is represented as 
I with subscripts of V and H, where the first letter indicates vertical or horizontal polarization of 
the excitation wavelength, and the second indicates the polarization of the emission lens. The G 
factor is a corrective value specific to each instrument and fluorophore, and is a measurement of 
a sample containing only the fluorescent molecule with horizontally polarized excitation (See 
equation 10).   
(10)    
   
   
 
A typical FP experiment used for binding affinity measurement uses multiple samples at 
identical fluorphore concentrations, where each sample has a different known concentration of 
the biological molecule it is binding. 
Fluorescence polarization, on the other hand, requires less specialized equipment since 
fluorescent readings are used in many types of research, and most commonly requires only an 
additional purchase of polarizing lenses.  Although adaptable to multi-well plate format for high-
throughput screening this usually requires more specialized instrumentation.  If a multi-well 
plate reader is available, FP can use less than 50 uL samples, so its protein requirement can be 
fairly minimal.  However low affinity interactions are not ideally suited for FP analysis, highly 
concentrated samples are needed leading to interference with anisotropy measurements, which 
can lead to sample scattering background through either protein aggregation of simply increased 
solution viscosity.  This can be overcome with IC50 competition experiments, but this is not 
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always possible unless another tighter binding molecule is known.  If this is the case, a label free 
technique such as SPR, ITC or a technique using radio-labels would be more appropriate.  
 
1.5.5 Surface Plasmon Resonance (SPR) 
As mentioned previously, SPR is one of the only techniques that continuously measures the 
kinetics of a binding event in real time.  SPR is an optical technique that relies on activation of 
surface plasmons at the interface of a liquid and metal (usually gold).  In SPR, the experiment is 
conducted with a metal chip where one side of the metal interacts with the optical system, and 
the other is a coated surface interacting with the liquid sample.  The coating is usually 
carboxylated dextran, but other surfaces can be used to minimize surface effects due to non-
specific interaction of the analyte with the coating. One binding partner is tethered to the dextran 
either directly by standard amine, thiol or aldehyde coupling or indirectly through interaction 
with an antibody coupled to the dextran surface. Light is reflected at a specific angle and 
wavelength from the side of the metal not interacting with the liquid.  The refractive index is a 
function of mass bound to the surface, and is sensitive to changes in the mass due to binding of 
analyte, so the refractive angle of the incident light changes as more mass is bound to the chips 
surface.  To perform a SPR experiment, as seen in Figure 1.7, an analyte is continuously flowed 
over the chip surface, and the changes in refractive index is recorded as a graph of response units 
(RU) versus time, where the RU reading is proportional to mass per surface area.
99
  By repeating 
this experiment at various concentrations, the combined data can be fitted to various kinetic 
models to calculate the rate-constants which can then be used to calculate the Kd.
100
  In the case  
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BIAcore Experiment: re-make this figure.
Y
Α-GST Antibody
Carboxyl group
Amine coupling
peptide
(BRCT)2-GST 
fusion
CM5 Sensor Chip
CM5 Sensor Chip
Y
Α-GST Antibody
Amine coupling
peptide
(BRCT)2-GST 
fusion
Carboxyl group
α-  tibody
Figure 1.7 Surface Plasmon Resonance Experiment with  α-GST Antibody. SPR 
experiments are based on a mass difference on the surface of a gold sensor chip.  As binding 
occurs and the mass changes on the surface, the angle of reflected light from the bottom of 
the chip changes, and is observed.  The most common chips are coated in dextran and 
therefore have carboxylic acids available for amine coupling of proteins to the surface.  The 
protein of interest can be directly coupled to the chip surface, or secondarily via an antibody 
as shown here.  Once the antibody is couple, the protein of interest immobilized on the 
surface via interaction with the antibody.  Peptide (or other ligand) is flowed over the chip 
surface and the response is measure.  On and off rates of binding are determined and used to 
find the binding affinity.  
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of incredibly fast binding kinetics when the on and off rates cannot be accurately determined, 
analysis of the binding at equilibrium at various concentrations is also possible.   
Although technically SPR is a “label free” technique, one component of the binding pair, 
ideally the smaller of the two, is required to be attached to the surface of a chip.  This can be 
problematic, because to optimize sensitivity the smaller molecule should be attached to the chip, 
and as with attaching a fluorescent tag, alteration of a smaller molecule has the potential to 
dramatically change the way it binds. Proteins are much easier to attach to the surface without 
altering the interacting interface; however, the additional mass increase from the binding of a 
small ligand is often insufficiently sensitive to acquire meaningful data.  Because this format is 
measuring binding at a liquid/solid interface and not solution phase binding, the experimental 
results can complicated by non-specific surface effects that may be observed.  In this case trying 
different chip surfaces may be required.  In the end, SPR is a great technique for direct 
observation of an interaction’s off and on rates, but it can be costly due to the necessary 
specialized equipment and maintenance, and is not amenable to a high-throughput format.   
 
1.5.6 Summary of Current Techniques  
The techniques discussed above are only some of the many that have been developed to 
study the interactions of biomolecules.  One of the reasons that so many techniques have been 
developed is that there are many advantages and disadvantages to each technique.  Each of these 
techniques is capable of measuring a Kd, but no single technique can produce all the information 
that is necessary to fully understand a binding interaction.  A summary of each technique can be 
found in Table 1.1. 
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Technique Advantages Disadvantages
Equilibrium
Ultrafiltration 
Binding Assay
• No special equipment needed
• Only small quantities of 
ligand needed due to 
sensitivity of radiolabeling
• Label-free technique
• Solution phase analysis
• Not as precise as other 
techniques
• Must have access to 
radiolabeled ligand
Isothermal 
Titration 
Calorimetry
• Allows determination of 
thermodynamic constants
• Label-free technique
• Solution phase analysis
• Narrow range of ligand 
affinity is suitable for this 
technique
• Expensive 
instrumentation and 
maintenance
Fluorescence 
Polarization
• Adaptable to high throughput 
screening (with appropriate 
instrumentation
• Solution phase analysis
• Can be adapted to small 
volumes
• Can be difficult to 
analyze low affinity 
ligands
• Requires addition of 
fluorescent tags, which 
can interfere with ligand 
binding
• Special instrumentation 
needed for high-
throughput analysis
Surface Plasmon 
Resonance
• Monitors on and off rates of 
interaction
• Label-free technique
• Surface effects from 
monitoring reaction on a 
chip
• Not amenable to high 
throughput screening
• Expensive 
instrumentation and 
maintenance
Table 1.1 Summary of Binding Affinity Techniques. Listed in this table are key 
advantages and disadvantages of several techniques to determine binding affinities 
of a ligand.  
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2.1 Introduction 
The standard set of amino acids has a wide variety of side chain redundancy.  For 
example, Glu and Asp, Gln, and Asn, and many of the hydrophobic amino acids (Leu, Ile) have 
similar side chains.  Therefore substitution of some of these with unnatural amino acids will 
expand the diversity of functional groups found in peptides.  In the setting of a library selection, 
in addition to library size, this expanded group of available functional groups will also increase 
the diversity found in the library potentially leading to selection of higher affinity peptides as a 
result.  Using the PURE translation system, substitution of natural with UNAAs is the simplest 
way to generate a large library containing many UNAAs. 
The basis of this method is leaving out one or more natural amino acids from the 
translation reaction and replacing them with corresponding UNAA analogs that can be charged 
by the natural aminoacyl-tRNA synthetases (AARS) onto the tRNA corresponding to the absent 
natural amino acids (Figure 2.1). A previous assay to discover unnatural amino acids that are 
substrates for AARS found over 92 UNAAs that can be successfully charged by simple 
substitution in the PURE translation system.
88b
 In this work we chose eight UNAAs (Figure 2.2) 
from this list for possible incorporation into our translation products, including two different 
possible tryptophan analogs. These amino acids are all commercially available in their Fmoc 
protected forms for solid phase peptide synthesis (SPPS) with the exception of canavanine.  
Additionally, the previous study found these UNAAs to be among the most efficiently 
incorporated using this substitution method, which makes them good candidates for use together 
in translation.  After selecting the group of UNAAs to incorporate the next step is to test each of 
them individually to assure results similar to previous findings, and if needed optimize each 
UNAA individually in translation before combining them.   
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F26 4-fluoro phenylalanine
L3 β-t-butyl alanine
V3 1-amino cyclopentanoic acid
I2 phenylglycine
R1 L-canavanine
P1  L-azetidine-2-carboxylic acid
Figure 2.2 UNAA Analogs.  These eight UNAAs were chosen to test 
for their suitability for use together in translation via substitution with 
their natural congeners.  The letter in the abbreviation shown in bold 
indicates the amino acid for which each analog will be substituted.
W2 4-fluoro-tryptophan
W3 o-methyl tryptophan
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2.2 Testing Individual Unnatural Amino Acids in PURE Translation 
Each of the eight UNAAs chosen was added to a translation reaction using one of the 
four mRNA test templates listed in Table 2.1.  Each translation was conducted on a 50 µL scale 
in duplicate with one reaction analyzed by MALDI-TOF-MS to monitor fidelity of translation 
and the other sample containing 
35
S-methionine to monitor yield by scintillation counting.  Each 
template encodes for a C-terminal FLAG and His6 epitope tag that allows for purification of the 
peptides from translation.  The C-terminal placement allows only for capture of full length 
peptides, so any truncations caused by inefficient incorporation of UNAAs are not observed.  
After capture of the peptides with either Ni-NTA or anti-FLAG antibody agarose, the translated 
peptides can be eluted and characterized via MALDI.  The results of these initial translations are 
shown in Figure 2.3a and b.  In each case of Figure 2.3 a MALDI analysis of a translation with 
all-natural amino reaction with a particular template is shown on the left, and a MALDI analysis 
of a translation reaction with an UNAA is shown on the right.  Each of these is the initial test of 
this particular amino acid.  The expected mass, and mass of the primarily observed peak is 
shown.  The translation test of amino acids L3, F26, R1 show high fidelity and yield; however, for 
the other three amino acids some optimization was required.   
 Troubleshooting yield and ﬁdelity.  
When UNAAs are not efficiently incorporated into a peptide during translation, the two 
types of errors that occur can generally be classified as either truncations or misincorporations.  
Truncation occurs when the UNAA is not an efﬁcient translation substrate, and there are no 
competing AAs or AA-tRNAs. Truncations can only be directly visualized by MS if an N-
terminal tag is used; however, in these experiments all mRNA templates encoded a C-terminal  
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Coding Region Epitope Tag
MHFSW DYKDDDDK
MTINR DYKDDDDK
NLEPQ DYKDDDDK
MVHM HHHHHHM
Table 2.1 mRNA Test Templates.  List of peptide-encoding sequences used to 
analyze analog translation. The full length mRNA sequences can be found in 
Ref 74.
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Figure 2.3a Initial MALDI Analysis of UNAA in Translation.  The four amino 
acid analogues listed on the left were tested for their ability to incorporation into a 
translated test peptide via substitution for their corresponding natural amino acid, 
and analyzed by MALDI.  The all-natural peptides  are indicated by white triangle, 
and the UNAA peptides are indicated by a black triangle.  The yields of the UNAA 
reaction compared to the all-natural is indicated.  The expected and observed mass 
is shown on each MALDI spectrum.  
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Figure 2.3b Initial MALDI Analysis of UNAA in Translation Continued. The 
four amino acid analogues listed on the left were tested for their ability to 
incorporation into a translated test peptide via substitution for their corresponding 
natural amino acid, and analyzed by MALDI.  The all-natural peptides  are indicated 
by white triangle, and the UNAA peptides are indicated by a black triangle.  The 
yields of the UNAA reaction compared to the all-natural is indicated.  The expected 
and observed mass is shown on each MALDI spectrum.
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tag. A low translation yield with C-terminally tagged peptide is also typically indicative of 
premature truncation.  
MALDI-TOF MS analysis provides information about the ﬁdelity of the translation and 
provides evidence of any misincorporation of other amino acids in place of the desired UNAA. If 
the anticipated peptide mass with the UAA is not observed, use of a misincorporation mass table 
(Figure 2.4) can be useful to quickly determine the identity of the misincorporated amino acid.  
Misincoporations typically are observed when either (1) a near-cognate AA-tRNA is able to 
compete effectively at the ribosomal A-site with the UNAA-tRNA containing a cognate codon, 
or (2) when residual natural amino acid competes with the unnatural variant for the AARS.  
Increasing the concentration of the UAA is typically the ﬁrst strategy we use to improve 
ﬁdelity and efﬁciency. Limiting factors to this strategy include the solubility of the UAA, as well 
as the possibility that very high concentrations may lead to competition with other AARS (if the 
UAA is charged onto tRNA by two different AARS). If increasing the concentration does not 
dramatically improve yield, we also typically try to increase the concentration of the appropriate 
AARS to enhance the rate of formation of the UAA-tRNA. 
If the UAA is a relatively poor substrate for an AARS, even trace amounts of the 
contaminating natural AA can be a problem. There are several potential sources of 
contamination. A common source is the amino acids themselves. For example, we have found 
that Gln is contaminated with Glu and Asn is contaminated with Asp. It is often helpful in these 
situations to lower the concentration of the natural amino acid that contains the contaminant 
amino acid. Another contaminant source is the E. coli total tRNA which does contain 
aminoacylated-tRNA species. These residual AAtRNAs can be removed by deacylation at pH  
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Figure 2.4 Misincorporation Table.  The values in the middle of the table 
correspond to changes in mass when changing from the amino acid on the top row 
to an amino acid on the left-side column. 
75 89 105 115 117 119 121 131 131 132 133 146 146 147 149 155 165 174 181 204
G A S P V T C I L N D K Q E M H F R Y W
75 G 0 -14 -30 -40 -42 -44 -46 -56 -56 -57 -58 -71 -71 -72 -74 -80 -90 -99 -106 -129
89 A 14 0 -16 -26 -28 -30 -32 -42 -42 -43 -44 -57 -57 -58 -60 -66 -76 -85 -92 -115
105 S 30 16 0 -10 -12 -14 -16 -26 -26 -27 -28 -41 -41 -42 -44 -50 -60 -69 -76 -99
115 P 40 26 10 0 -2 -4 -6 -16 -16 -17 -18 -31 -31 -32 -34 -40 -50 -59 -66 -89
117 V 42 28 12 2 0 -2 -4 -14 -14 -15 -16 -29 -29 -30 -32 -38 -48 -57 -64 -87
119 T 44 30 14 4 2 0 -2 -12 -12 -13 -14 -27 -27 -28 -30 -36 -46 -55 -62 -85
121 C 46 32 16 6 4 2 0 -10 -10 -11 -12 -25 -25 -26 -28 -34 -44 -53 -60 -83
131 I 56 42 26 16 14 12 10 0 0 -1 -2 -15 -15 -16 -18 -24 -34 -43 -50 -73
131 L 56 42 26 16 14 12 10 0 0 -1 -2 -15 -15 -16 -18 -24 -34 -43 -50 -73
132 N 57 43 27 17 15 13 11 1 1 0 -1 -14 -14 -15 -17 -23 -33 -42 -49 -72
133 D 58 44 28 18 16 14 12 2 2 1 0 -13 -13 -14 -16 -22 -32 -41 -48 -71
146 K 71 57 41 31 29 27 25 15 15 14 13 0 0 -1 -3 -9 -19 -28 -35 -58
146 Q 71 57 41 31 29 27 25 15 15 14 13 0 0 -1 -3 -9 -19 -28 -35 -58
147 E 72 58 42 32 30 28 26 16 16 15 14 1 1 0 -2 -8 -18 -27 -34 -57
149 M 74 60 44 34 32 30 28 18 18 17 16 3 3 2 0 -6 -16 -25 -32 -55
155 H 80 66 50 40 38 36 34 24 24 23 22 9 9 8 6 0 -10 -19 -26 -49
165 F 90 76 60 50 48 46 44 34 34 33 32 19 19 18 16 10 0 -9 -16 -39
174 R 99 85 69 59 57 55 53 43 43 42 41 28 28 27 25 19 9 0 -7 -30
181 Y 106 92 76 66 64 62 60 50 50 49 48 35 35 34 32 26 16 7 0 -23
204 W 129 115 99 89 87 85 83 73 73 72 71 58 58 57 55 49 39 30 23 0
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8.8 followed by dialysis.   Examples of how these strategies can be applied are shown below for 
the optimization of P1, V3, and W3 
Optimization of P1 
 Significant enhancement of P1 incorporation was seen upon doubling the analog 
concentration from 200 µM to 400 µM (Figure 2.5).  Supplementation of proline aminoacyl-tRNA 
Synthetase (PRS) was attempted to enhance yield of incorporation, but without success.  
Optimization of V3  
One UNAA that we have shown can be incorporated with reasonable efﬁciency into 
peptides via translation is 1-aminocyclopentanoic acid (V3). To test its incorporation we used the 
template encoding MVHMH6M.  Monitoring incorporation by MALDI-TOF in templates 
containing a hexahistidine tag can be complicated by glutamine misincorporation.  We presume 
that this misincorporation arises because the high proportion of His codons and low overall 
abundance of tRNA
His
 leads to depletion of His-tRNA
His
 during translation.  The 
misincorporation results in serial -9 peaks in the MALDI spectrum corresponding to the number 
of glutamine misincorporations.  
The initial translation experiment showed only a tiny amount of V3 incorporation; the 
majority of the peptides contained valine.  Because no valine is added to the translation reaction, 
the issue with V3 incorporation is the presence of competing valine as a contaminant.  Using 
deacylated tRNA significantly improved incorporation efficiency, suggesting that Val-tRNA
Val
 
present in the commercial tRNA mix was the culprit.  To deacylate the total tRNA, it is treated at 
pH 8.8 followed by dialysis to remove any amino acids that had been deacylated.  This 
deacylated tRNA led to a dramatic increase in the V3 peptide fidelity (Figure 2.6).  Using this  
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1 mM 2 mM
Yield: 57 % Yield: 68 %
Figure 2.5 Titration of P1 Analogue in Translation.  In attempt to 
increase the fidelity of incorporation of the P1 analogue, its concentration 
was increased in the translation reaction.  The expected and observed 
masses are shown on each MALDI spectrum, and the yield compared to 
an all-natural amino acid translation is shown below. 
LEP1Q
Exp: 1625.67
Obs: 1641.87
LEP1Q
Exp: 1625.67
Obs: 1641.45
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Yield: 71 %
Δ
Δ
Δ
MV3HM
Exp: 1512.56
Obs: 1512.62
Yield: 67 %
Yield: 93 %Yield: 83 %
VE
Δ
Δ
Δ
Δ
Δ
MV3HM
Exp: 1512.56
Obs: 1512.45
MVHM
Exp: 1512.56
Obs: 1512.45
MVHM
Exp: 1512.56
Δ
Δ
Untreated tRNA + V3 Deacylated tRNA + V3
Deacylated tRNA
No ValRS
Deacylated tRNA
No Val
Figure 2.6 V3 Incorporation with Deacylated tRNA. Fidelitiy of 1-amino-
cylcopentanoic acid (V3) incorporation in place of valine in a template encoding 
MVHMH6M. A-B) Comparison of the effect on translation fidelity  of V3 incorporation 
with untreated and deacylated tRNA. C-D) Translation reactions were also conducted in 
the absence of either valine amino-acyl tRNA Synthetase (ValRS) or without valine.  
Yields of each reaction compared to an all-natural amino acid translation with all 
components are indicated.  V3 incorporation is indicated by black arrows and valine 
with white arrows.
A B
C D
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deacylated tRNA, we varied the concentration of V3 and showed that 6.4 mM was the best 
concentration to use in translation (Figure 2.7).  Use of deacylated tRNA did not lower the yield 
significantly of any of the peptide templates (Figure 2.8).  
Optimization of W3 
A translation experiment was conducted along with the F26 and R1 analogs that are also 
found in the HSFW template.  Knowing that these two analogs incorporate very well and will 
likely be used in the final selection experiments W3 is of little use to us if it cannot be 
incorporated along with the other analogs. In another experiment, the concentration of W3 was 
significantly increased to 1.6 mM based on the available volume in the translation reaction, but 
despite this increase the expected mass was not observed at all (Figure 2.9).  When a simple 
concentration increase failed to produce any W3 incorporation, additional TrpRS was added to 
the translation, but this modification was also unsuccessful (Figure 2.10). 
Optimization of I2 
The primary issue seen with the incorporation of the I2 analog is the significant Ile 
incorporation that is seen in addition to the analog.  Since no Ile was added to the translation 
reaction, it had to be present as a contaminant in one of the reaction components.  When 
increasing the I2 concentration up to 3.2 mM showed no improvement in out-competing the 
natural Ile for incorporation (Figure 2.11).  Deacylated tRNA was tested as one means of 
contaminant removal (Figure 2.12). The source of Ile contamination does not appear to be from 
Ile-tRNA
Ile
 because despite using treated tRNA, the misincorporations have the same pattern as 
untreated tRNA. Likely the Ile is a contaminant in another reaction component, perhaps a natural 
amino acid and is present in sufficient quantities to out compete I2 for the most part.  This type of  
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ΔΔ
MV3HM
Exp: 1512.56
Obs: 1512.45
Yield: 94 %
3.2 mM
Yield: 81 %
Yield: 60 %Yield: 68 %
Δ
MV3HM
Exp: 1512.56
Obs: 1512.40
MV3HM
Exp: 1512.56
Obs: 1512.48
MV3HM
Exp: 1512.56
Obs: 1512.45
Δ
Δ
Δ
Δ
Δ
Δ
Δ
Δ
Δ
Δ
Δ
6.4 mM
12.8 mM 19.2 mM
Figure 2.7 Titration of V3 Concentration with Deacylated tRNA. In 
attempt to increase fidelity of V3 incorporation, translation reactions were 
conducted with tRNA as well as increasing V3 concentrations as indicated.  
The expected and observed masses are indicated, as well as the reaction 
yields.  V3 incorporation is indicated by the black triangles and valine with 
white.  
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Figure 2.8 Effect of Deacylated tRNA on Peptide Yield.  In order to asses a 
general effect of deacylated tRNA on peptide yield, translations were conducted 
with the test peptides.  The graph shows the percent yield compared to 
translations with untreated tRNA. 
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1.6 mM
HF26SW3
Exp: 1761.68
Obs: 1721.87
12 µM TrpRS
HF26SW3
Exp: 1761.68
Obs: 1667.95
Figure 2.9 Increase in Concentration to Improve W3 Fidelity. A 50 µL 
translation with an increased concentration of W3 in attempt to increase its 
incorporation.  The peptide product was not observed.
Figure 2.10 Increase in  to Improve W3 Fidelity. A 50 µL translation with an 
increased concentration of Tryptophan amino-acyl synthetase (TrpRS) in final 
attempt to observe its incorporation. The peptide product was unable to be 
identified.  
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3.5 mM
Δ
TI2NR1
Exp: 1676.84
Figure 2.11 Incorporation of Analogue I2 with a High Amino Acid 
Concentration.  Despite the high concentration of the I2 analogue in the 
translation reaction, no peak with the expected mass was observed.  However 
a peak corresponding to the all-natural peptide was seen and is marked with 
a triangle.  
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1 hour
Deacylated
2 hour
Deacylated
Un-treated 
tRNA
TINR
TINR
TINR
TI2NR
TMNR
TI2NR
TMNR
TMNR
TI2NR
Figure 2.12 Analogue I2 Deacylation Tests. To test the effect of tRNA deaclyation on the
fideltity of I2 incorporation, 50 µL translations were conducted with untreated, deacylated
tRNA that had been treated with base for either 1 hour or 2 hours.  Misincorporations are 
marked with an underline.
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contaminant can be more difficult to remove, and it was decided not to include I2 in the UNAA 
mix for selection.   
 
2.3 Combination of UNAAs in PURE Translation 
Efﬁcient incorporation of the UAA into a single template does not guarantee that it will 
be efﬁciently incorporated into peptides when combined with other analogs.  Before progressing 
to translation with the library templates, it was necessary to test all of the UNAAs with each of 
the templates.  One reaction contained all the FLAG templates, and the other the single His6 
template, but both had all 6 desired UNAAs.  The results from these tests  (Figure 2.13) showed 
expected fidelity and yield based upon prior testing of individual amino acids, so testing with 
library templates was pursued.  The final concentration of amino acids used in translation can be 
found in Table 2.2. 
2.4 Testing UNAAs with Library Templates 
 After successful translation of the six final peptides in the same translation 
reaction a final assessment of the effect of UNAA incorporation on peptide yield was assessed 
using the actual template to be used in the selection (Figure 2.13). It is not possible to observe 
the peptides encoded by the randomized library because in theory they should each have 
different sequences. Thus fidelity is assumed to be the same as that observed in previous 
experiments. When the translation reactions with library mRNA templates were supplemented 
reaction (Figure 2.14).  
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Figure 2.13 Translation with All Six UNAAs.  For a final test of translation fidelity 
with all six UNAAs, two 50 µL translations were conducted with all six UNAAs 
present.  A) The translation reaction containing the three FLAG-tagged templates.  
Peptide products containing UNAAs are marked with arrows, and the expected and 
observed masses are written.  B) Another translation was conducted with the MVHM 
His6-tagged template. V3 incorporation is marked with black arrows, and valine 
incorporation with gray arrows.  
MVHM
HF26SW2
Exp: 1748.92
Obs: 1750.22
TINR1
Exp: 1658.78
Obs: 1660.16
L3EP1Q
Exp: 1639.82
MV3HM
Exp: 1510.70
Obs: 1511.79
A
B
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Amino Acid/Synthetase Symbol
Concentration in 
Translation Reaction
4-fluoro-DL-tryptophan Wa 0.8 mM
L-canavanine Ra 0.4 mM
L-azetidine-2-carboxylic acid Pa 1.0 mM
4-fluoro-phenylalanine Fa 1.6 mM
β-t-butyl-L-alanine La 6.6 mM
1-aminocyclopentane-1-carboxylic acid Va 6.4 mM
Prolyl aminoacyl-tRNA Synthetase PRS 0.31 µM
Table 2.2 Final Concentration of Unnatural Amino Acids and PRS.  These are 
the only deviations to the in vitro translation reaction conditions described by Ma 
and Hartman (Ref 101).
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Figure 2.14 Yield of All 6 UNAAs with Library Templates. 250 µL translations 
were conducted with the CX12 library template that will be used for selection to 
compare the yield of incorporation of the six UNAAs to an all-natural amino acid 
translation.  
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2.5 Discussion  
In search of a bioavailable and high affinity peptide, unnatural amino acids were 
substituted for some of the 20 natural amino acids in translation.  Based on our previous work 
describing amino acid analogs that can be incorporated by substitution in ribosomal 
translation,
101
 a group of six unnatural amino acids were optimized for use together with the 
other 14 natural amino acids in translation.  Translational efficiency was measured by 
35
S-Met 
incorporation, and translational fidelity was determined by MALDI-TOF analysis.  Amino acid 
analogs W2, F26, R1 and L3 were incorporated with high efficiency in place of their natural 
congeners; however, additional modifications were required for incorporation of the W3, I2 and 
V3 and P1 analogs.  Attempts to increase amino acid concentration and add the corresponding 
AARS or use deacylated tRNA were unsuccessful in achieving high fidelity incorporation of the 
W3 and I2 analogs.  However, treatment of total E. coli tRNA with mildly basic conditions to 
remove residual Val-tRNA
Val
 along with addition of higher V3 concentrations was sufficient to 
remove the majority of valine contamination in translated peptides allowing successful 
incorporation of the V3 analog.
102
  Attempts to improve the yield of P1 by increasing its 
concentration in the reaction were successful; however, improving yield by supplementing the 
translation reaction with additional proline aminoacyl-tRNA Synthetase (PRS) was unsuccessful.   
Because W3 was unable to be successfully optimized and was therefore replaced with the 
efficiently incorporated W2 analog, while I2 was dropped altogether.   
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2.6 Experimental 
General Reagents  
Putrescine, spermidine, potassium chloride (KCl), ammonium chloride, magnesium acetate 
tetrahydrate (Mg(OAc)2), calcium chloride (CaCl2), potassium hydroxide (KOH), nucleoside 5´-
diphosphate kinase from bovine liver, D,L-dithiothreitol (DTT), myokinase from rabbit muscle, 
adenosine 5´-triphosphate disodium salt, guanosine 5´-triphosphate sodium salt hydrate, ANTI-
FLAG M2-Agarose from mouse, triﬂuoroacetic acid spectrophotometric grade and a-cyano-4-
hydroxy-cinnamic acid were purchased from Sigma–Aldrich. Potassium acetate (KOAc), water 
Optima LC/MS grade and acetonitrile Optima LC/MS grade were purchased from Fisher. 
Potassium phosphate dibasic (K2HPO4) was purchased from Caledon. Creatine kinase and 
Escherichia coli total tRNA were purchased from Roche Applied Science. Creatine phosphate 
potassium salt was purchased from Merck/EMD. (6R,S)-5,10-formyl-5,6,7,8-tetrahydrofolic acid 
(methyl tertahydrofolate) was purchased from Schircks Laboratory. All natural L-amino acids 
were purchased from Fluka in their highest purity form. 35S-Met (Speciﬁc Activity: >1000 Ci 
(37.0 TBq)/mmol) was purchased from Perkin-Elmer. 1-Aminocyclopentanoic acid was 
purchased from Chem-Impex International. Zip Tip C-18 columns were purchased from 
Millipore. Ni-NTA agarose was purchased from Qiagen. 
Amino acids.  Unnatural amino acid sources: Wa: 4-fluoro-DL-tryptophan (Sigma), Ra: L-
canavanine (Sigma), Pa: L-azetidine-2-carboxylic acid (ChemImpex), Fa: 4-fluoro-L-
phenylalanine (ChemImpex), La:  beta-t-butyl-L-alanine (ChemImpex), and Va: 1-
aminocyclopentane-1-carboxylic acid (ChemImpex).  All natural amino acids were purchased 
from Fluka in their highest purity form.  All amino acids were dissolved in H2O at a 
concentration of 10 mM or at maximal solubility and KOH was added to a final pH of 7.0-7.5 
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followed by sterile filtration.  Isotopically labeled 
35
S-Met (1000 Ci/mmol) was from Perkin 
Elmer.   
Translation Factors, Enzymes and Ribosomes.  All purified enzymes were stored at -80 °C in 
enzyme storage buffer (50mM HEPES-KOH pH 7.6, 100mM KCl, 10mM MgCl2, 7mM BME, 
30% glycerol) with the exception of MetRS which was kept in enzyme storage buffer with 50% 
glycerol at  -20 °C.  Ribosomes were prepared as described.
103
  
Instrumentation 
MALDI-MS experiments were performed on a Micromass MALDI-R MALDI-TOF Mass 
Spectrometer. 
Preparation of mRNAs for Translation  
mRNAs were prepared using T7 in vitro transcription according to described protocols.
88a
 The 
DNA templates were created using two different methods. The ﬁrst method involved ligating 
synthetic DNA duplexes with sticky ends into a pET12b vector, followed by PCR using the 
primers complementary to the vector encoded T7 promoter and terminator. Alternatively, a 
single synthetic oligonucleotide complementary to the T7 promoter, Epsilon enhancer, Shine-
Dalgarno, and coding region was used as a template for runoff T7-mediated in vitro 
transcription.  
Preparation of Amino Acid Stocks for Translation 
Each UAA was dissolved to a ﬁnal concentration of 10 mM, the pH was adjusted to 7.0–7.5 with 
1 M KOH, ﬁltered through 0.22 µm syringe ﬁlter, and stored at -20 °C 
In vitro Translation 
Each translation reaction was carried out as previously described.
88a
 Each reaction (50 µL) 
contained putresciene (8 mM), spermidine (1 mM), potassium phosphate (5 mM), potassium 
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chloride (95 mM), ammonium chloride (5 mM), magnesium acetate (5 mM), calcium chloride 
(0.5 mM), dithiothreitol (1 mM), inorganic pyrophosphatase (1 µg/mL), creatine kinase (4 
µg/mL), nucleotide diphosphate kinase (1.1 µg/mL), (6R,S)-5,10-formyl-5,6,7,8-tetrahydrofolic 
acid (30 lM), myokinase (3 µg/mL), creatine phosphate (20 mM), ATP (2 mM), GTP (2 mM), E. 
coli total tRNA (2.4 mg/mL), IF-1 (1 µg), IF-2 (2 µg), IF-3 (0.75 µg), EF-G (1 µg), EF-TS (1 
µg), EF-Tu (2.24 µg), RF-1 (0.5 µg), RR-F (0.5 µg), RF-3 (0.5 µg), ribosomes (0.5 µM), 35S-
Methionine (0.4 µM), methionine (10 µM), 19 AA (200 µM), MetRS (0.1 µM), LeuRS (0.3 
µM), GluRS (0.6 µM), ProRS (0.2 µM), GlnRS (1.0 µM), HisRS (1.0 µM), PheRS A294G (2.5 
µM), TrpRS (1.5 µM), SerRS (0.2 µM), IleRS, (0.2 µM) ThrRS (0.4 µM), AsnRS (0.6 µM), 
AspRS (0.6 µM), TyrRS (0.5 µM), LysRS (0.5 µM), ArgRS (0.4 µM), ValRS (0.2 µM), AlaRS 
(0.2 µM), CysRS (0.5 µM), GlyRS (0.6 µM), MTF (0.2 µM) and mRNA template (1.14 µM).  
 The translations were initiated by addition of the appropriate mRNAs. For initial testing 
of UAAs, 19 natural amino acids were included (200 µM each) with only one UAA. After 
incubation of the translation for 1 h at 37 °C, the reactions were quenched with 150 µL PBS (if 
using FLAG tag) or 150 µL TBS with 5 mM BME (if using His-tag). Forty microliters of Ni-
NTA resin or 10 µL ANTI-FLAG M2 agarose was added to a 500 µL centrifugal ﬁlter along 
with the quenched translation reaction, and the mixture was tumbled at room temperature. After 
1 h, the resin was washed three times with 500 µL TBS and eluted with 1% triﬂuoroacetic acid 
(TFA) (50 µL). For reactions labeled with 35S-Met, the yield was determined by scintillation 
counting of half (25 µL) of the elution. To examine the ﬁdelity of the UAA incorporation, the 
non-radiolabeled reactions were puriﬁed and concentrated by Zip-Tip C18 chromatography. The 
Zip-tips were ﬁrst wetted with acetonitrile, followed by 1:1 acetonitrile, then with 0.1% TFA. 
Then the peptide was loaded onto the tip by pipetting up and down 15 times in the peptide 
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solution. The tip was washed three times with 0.1% TFA, and then eluted with 5 µL CHCA 
matrix (a-cyano-4-hydroxycinnamic acid in 1:1 MeCN:0.1% TFA). An aliquot (1 µL) of the 
resulting suspension was spotted on a MALDI plate and analyzed. 
tRNA Deacylation 
E. coli total tRNA (100 mg/mL) dissolved in 1 M Tris–HCl (pH 8.8) and was incubated at 37 °C 
for 2 h, followed by dialysis overnight at 37 °C against 50 mM Tris–HCl (pH 8.8). The tRNA 
was precipitated by ﬁrst adding 0.1 volume of a solution of KOAc (3.0 M, pH 5.5) and 3 
volumes of ethanol. The pellet was washed twice with 70% ethanol, and allowed to air-dry at 
room temperature. The tRNA was resuspended in ddH2O and the concentration was adjusted to 
100 mg/mL (1.6A260/µL). The tRNA was aliquoted and stored at -80 °C. 
 
2.7 Summary 
 Of the eight UNAA tested, six were found to work well together in translation.  The F26, 
W2, L3 and R1 analogs were successful in initial testing.  P1 and V3 required increased amino acid 
concentration to be successfully incorporated, with V3 also requiring the use of deacylated 
tRNA.  W2 and I2 on the other hand were not able to be incorporated with high fidelity despite 
modifications to the translation reactions.  Fidelity of these UNAA incorporations was 
maintained when they were combined, and overall yield was 30% of the all-natural yield with 
library templates. 
Future Directions.  These 6 UNAAs will be used together in translation for mRNA display 
selection against the (BRCT)2 domain of BRCA1.   
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CHAPTER 3. STRENGTH IN NUMBERS: mRNA-DISPLAY LIBRARY SELECTION 
AGAINST BRCA1-(BRCT)2 
 
 
 
Contributions: 
Zhong Ma and ERW performed experiments leading to the optimization of selection as well as 
the actual selection experiments. 
Melissa B. Huie, was responsible for cloning of GST-(BRCT)2 fusion protein.    
  
65 
 
3.1 Introduction 
Perhaps the best studied (BRCT)2 domain protein is BRCA1.  This protein is involved in 
various DNA repair pathways, and its C-terminal tandem BRCT domain
36c, 45, 104
 is known to 
bind selectively to phosphoprotein partners. The well-defined and relatively small binding cleft 
of the (BRCT)2 domain, and the fact that the many mutations that occur in this domain lead to 
chemotherapeutic and radiation sensitization by disruption of DNA repair, make it a promising 
therapeutic target.
105
  In addition, BRCA1 is involved in at least three different protein 
complexes mediated by the (BRCT)2 domain.
106
  Its involvement in each of these dynamic 
complexes is dependent on the cell cycle and on the extent of DNA damage.   Inhibitors of this 
domain would therefore allow dosable and temporal control of BRCA1 complex formation.   
High throughput in vitro small molecule screens have uncovered molecules that bind to 
BRCA1 in the 5-10 micromolar range,
47a
 yet their activity in cell culture and target selectivity 
have not been established. Currently, the best binders of this domain are phosphoserine-
containing peptides.  Several phosphopeptide library screens as well as comparisons of 
endogenous protein binders have determined that the preferred binding sequence for this domain 
is phosphoserine (pS)-X-X-F.
104, 107
  Libraries lacking phosphoserine were shown not to bind.
104, 
107
  Natarajan and coworkers have used rational design to optimize binding based on pS-X-X-F 
and have recently found a pS-containing modified tetrapeptide with a Kd of 40 nM.
108
 A recent 
report showed this phosphopeptide can abrogate BRCA1 function, but the effect was minimal 
and required high concentrations of peptide making it far from a useful therapeutic or tool.
49
  
Yet, attempts to replace phosphoserine with phosphomimetic groups have led to dramatically 
weakened binding affinity.
48b, 109
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We reasoned that by using a peptide library of sufficient size and functional diversity, a non-
pS containing peptide could be found that binds to the (BRCT)2 domain of BRCA1. There are 
many methodologies that have been developed for creation of peptide libraries, but mRNA 
display
110
 provides advantages over other techniques because of the potential for incorporation of 
non-canonical amino acids
111
 as well as the ability to prepare libraries with up to 10
13
 unique 
peptides,
110b, 111c
 3-6 orders of magnitude more diverse than is possible with on-bead synthesis or 
phage display.  With this increased diversity may come an improved chance of finding higher 
affinity peptides.
112
   
In choosing these UNAAs we have purposefully left out phosphoserine which has been 
regarded in the literature as a requirement for binding to the BRCA1-(BRCT)2 domain.  
Additionally, attempts to incorporate phosphomimetic analogs into BRCA1-(BRCT)2 binding 
peptides have not found great success and in many cases nearly abolish peptide binding.  We 
hope to uncover an alternative means of binding to this domain that is not reliant upon 
phosphoserine.  Such a peptide would be more amenable for use as a drug owing to increased 
stability and cell permeability. 
   
3.2 Selection Preparation and Optimization 
Library Design.  The DNA library contained a 12 amino acid random region encoding the 
peptide sequence MCX12GSGSLaGH6RaLa, with the random, X, amino acids designated by the 
codon NNB (B = G, T or C) (Figure 3.1A).  Usage of this codon vs. the standard NNS/NNK 
served to decrease the number of stop codons present in the random region (1/48 vs. 1/32 for 
NNS/K) while also increasing the likelihood of a second Cys (2/48 vs. 1/32) such that  
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Figure 3.1 Library Design.  Peptide library design for selection against the 
(BRCT)2 domain of BRCA1. A) the mRNA sequence encoding the peptide 
library including an N-terminal fix cysteine (red) followed by a 12 amino acid 
random region (black and gray), a Gly-Ser linker (green) and a His6 tag (blue).  
B) A codon table displaying remaining available codons with use of the NNB 
codon where B = G, C, or T, thus eliminating two of three potential stop codons 
and enriching the presence of cysteine in the library.  C) Cyclization of library 
members with an additional cysteine in the random region will be accomplished 
via a cyclization reaction with dibromoxylene.  
1
SH
HS
A
B
C
NNB = semi-random codon
Where N = (A, G, C, or T)
and B = (G, C, or T) 
AUGUGCNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBGGCUCCGGUAGCUUAGGCCACCAUCACCAUCACCAU
Met  Cys X      X X X X X X X X X X X Gly Ser Gly Ser Leu Gly His  His His His His His
mRNA
peptide
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approximately 40% of the initial library should contain at least one additional Cys (Figure 3.1B).  
The addition of a second cysteine was desired to enable cyclization with α-α’-dibromo-m-xylene  
(Figure 3.1C).
111c, 113
  Cyclization is beneficial because it can enhance affinity, cell permeability, 
and stability.
114
 
Expression of GST-(BRCT)2 fusion (01-85) 
 The BRCA1 (BRCT)2 had previously been cloned into pGEXx4T-1 vector for expression 
as an N-terminal glutathione S-transferase (GST) fusion.  Using a BL21 Codon Plus (DE3) RIL 
strain, the protein was expressed via ZYM-5052 auto induction overnight at 18 °C.
115
 The 
protein was purified with tandem Ni-NTA agarose (Qiagen) and Glutatione agarose (Thermo) 
affinity resin and gave 3 mg/L culture.  Resultant protein was > 95 % pure by SDS-PAGE 
analysis (See Figure 3.2), and was stored in enzyme storage buffer at -80 until needed.   
Capture and Release of GST-(BRCT)2 with Magnetic GSH Beads In order to perform the 
capture and elution of the library it is necessary to optimize the binding and release of the protein 
from its immobilized support.   An initial test of bead binding and elution (Figure 3.3A) showed 
an acceptable level of protein fusion binding to the bead; however a significant amount of 
protein remained on the beads after four rounds of exposure to 120 µL elution buffer (125 mM 
Tris pH 8.25, 50 mM GSH, 500 mM NaCl, 1 % Triton X-100) for 10 minutes each.  To improve 
the elution, we tested four buffers noted for their enhanced stringency: 1) 250 mM Tris pH 9.0, 
100 mM GSH, 500 mM NaCl, 1 % Triton X-100, 2) 125 mM Tris pH 7.5, 500 mM NaCl, 0.1 % 
SDS, 5 mM DTT, 3) 100 mM Glycine pH 2.85, 500 mM NaCl, 0.1 % Triton X-100, 4) Boiling 
in TBS (50 mM Tris pH 8.0, 300 mM NaCl) for 5 minutes.  
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Figure 3.2. SDS-PAGE Analysis of Purified Fusion Proteins.  Analysis 
of purified BRCT fusions by SDS-PAGE and staining with Coomassie Blue
shows proteins estimated to be >95% pure.  The expected mass of GST-
BRCT is 51.3 kDa, and TR-BRCT is 42.9 kDa.
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Figure 3.3 Elution of GST-(BRCT)2 Fusion from Glutathione Beads. Only 
peptides bound to immobilized GST-(BRCT)2 that is successfully eluted will be 
carried on in the next round of selection so it is important that as much of the fusion 
be eluted as possible after selection. A) An initial test of the protein fusion binding 
an elution shows significant protein fusion remaining on the beads (see lane on far 
right). B) Four elution buffers (see text for details) were tested to find a more 
stringent buffer capable of complete elution of the protein fusion.  
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After one round of elution with 200 µL for 10 minutes, buffers 1 and 2 left no detectable protein 
bound to the bead (Figure 3.3B).  Buffer 1 was chosen for use in the library selection.  
  
3.3 mRNA Display Library Selection Against BRCA1-(BRCT)2 
The general scheme of the selection process is shown in Figure 3.4.  The mRNA peptide fusion 
library was prepared in the standard way.
111c, 116
  Briefly, mRNA was photocrosslinked onto a 
puromycin-DNA linker.  After translation in the presence of unnatural amino acids, a library of 
mRNAs covalently linked to the peptides they encoded was formed.  The mRNA-peptide fusions 
were purified via Oligo-dT cellulose and cyclized on the resin, followed by reverse transcription 
and Ni-NTA purification.  The translation was performed on a large (10 mL) scale for round 1 
leading to the creation of 1.3 x 10
13
 mRNA peptide fusions, each theoretically unique.  The 
(BRCT)2 domain of BRCA1 was prepared as N-terminal GST-fusion.  This fusion protein was 
immobilized onto glutathione (GSH) magnetic beads, and the mRNA peptide fusions were 
allowed to bind.  Bound mRNA-peptide fusions were sequestered using a magnet, followed by 
several washes.  Elution of the GST fusion from the beads was achieved via competition with 
excess GSH.  PCR of the mRNA-peptide fusions amplified the recovered fusions.  The resulting 
DNAs were in vitro transcribed and the process repeated iteratively.  The percentage of the 
eluted 
35
S-Met-containing mRNA-peptide fusions vs. the total input was calculated in each 
round.  In the first six rounds, very little enrichment was seen, but after the initial spike in round 
seven, the beginning of a plateau was seen in round 8 (Figure 3.5).  
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Figure 3.4 In vitro Selection Scheme. The DNA library encodes a twelve amino acids 
random region with an N-terminal cysteine.  After peptide fusion formation, peptides 
with a second cysteine are cyclized with dibromoxylene.  Purified mRNA-peptide 
fusions undergo reverse transcription and his-tagged purification before being selected 
for binding to the GST-(BRCT)2 fusion immobilized on magnetic resin.  Unbound 
peptides are washed away and bound peptides are eluted, PCR amplified, and carried 
through another round of selection.  Structural representation of the BRCA1 (BRCT)2
domain was adapted from PDB entry code 1T29 using the PyMOL molecular graphics 
system (Schrodinger, LLC).
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Figure 3.5 Selection Progress. The percentage of 35S-Met labeled peptide eluted 
with GSH relative to the total 35S-Met input from each round of selection was 
calculated and is shown for each of eight rounds.  
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3.4 Sequencing 
After the plateau beginning in the eighth round, the cDNAs corresponding to the selected 
peptides were sequenced following cloning.  As shown in Figure 3.6, of the 85 sequences found, 
7 sequences appeared more than once, and these duplicate sequences comprised more than 80 % 
of the total sequencing hits.  Alignment of the top seven sequences is shown in Figure 3.7. 
 
3.5 Discussion 
Unnatural amino acids appeared many times in the random region of the selected 
sequences, but the variety of different amino acids was limited to primarily F26 and R1.  Analogs 
L3 and P1 were present in families 8.3/8.4 and 8.7 respectively, while V3 and W2 were limited to 
single appearances in the “other” sequences.  The most notable motif is the recurring D/E-X-X-
Fa sequence that is found in 80 of the 85 sequences.  This motif is remarkably similar to the pS-
X-X-F motif known to be found in all known BRCA1 (BRCT)2-domain binding proteins,
106, 117
 
where the Phe is replaced with 4-fluoro-Phe and the pSer is replaced with either aspartic or 
glutamic acid, both being known, but weak pS-mimetics.
118
  These results were somewhat 
surprising, because prior attempts to mutate pS to E led to abrogated BRCA1 binding.
109
  
Previously oriented SPOT library screens have shown that peptides containing β-branched and 
aromatic AAs in the X-X positions are preferred.
107
  This preference is also mirrored in many of 
our sequences. 
 
3.6 Experimental 
Protein Expression.  The plasmid construct containing the BRCA1 (BRCT)2 domain (amino 
acids 1646-1859)
119
 was digested with restriction enzymes NdeI and XhoI.  PCR amplification  
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6
Figure 3.6 Selection Sequencing Results. After round eight, cDNA from the 
library pool was cloned and sequenced giving the 85 sequences shown, and 
similar sequences were arranged into 7 families.  Unnatural amino acids are 
designed in red. 
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MCNDFIFRRSTFRA
MCSDFIFSRRTYTF
MCNDFTFDKNLNHH
MCHNDFAFAKTSLY
MCYDFDTTNDHTFI
MCTIDFDEYRFRKT
MCDFQFRKPSTTIY  
D F I F
pS X X F
Consensus Seq
Aromatic Branched
Selection
Prior studies5pS Prior Selection Studies
DXXF
8.1
8.2
8.3
8.4
8.5
8.6
8.7
Figure 3.7 Family Sequence Alignment.  The top seven families are aligned 
with respect to the D/E-X-X-F motif found in each family (emphasized with 
a gray rectangle).  Un-nautral amino acids are indicated in red.  
77 
 
with primers BRCT FWD (5’-CGGGATCCGTCAACAAAAGAATGTCCATGGTGGTGTC-
3’) and REV (5’-CCGCTCGAGTCAGTGGTGGTGGTGGTGGTGGGGGATCTGGGGTATC-
3’) were used to amplify the insert creating a BamHI restriction site at the N-terminus and adding 
a hexahistidine tag to the C-terminus.  The insert was then ligated into a pGEX-4T-1 vector to 
form a C-terminal Glutathione S-Transferase (GST) fusion which was then verified by 
sequencing.  After transforming into E. coli strain BL21(DE3)-RIL cells, protein expression was 
induced with auto-inducing ZYM-5052 media
120
 with overnight incubation at 18 °C. 
Additionally a modified pET32a vector previously described
121
 was used to prepare an N-
terminal thioredoxin fusion with C-terminal His-tag (TR-BRCT).  The pGEX-4T-1 vector was 
digested with BamHI and XhoI and ligated into the modified pET32a.  After transformation into 
BL21 (DE3) strain of E. coli, cells were expressed using auto-inducing media overnight at 
18 °C.
115
 The recombinant protein was purified via tandem affinity purification, first with 
binding to Ni-NTA agarose (QIAGEN) while tumbling at 4 °C for 60 minutes.  After washing 
twice (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 5mM BME), six elutions (1.5 ml 
each of 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, 5 mM BME) were combined an 
dialyzed overnight into 1X PBS.  After dialysis, protein was combined with glutatione-agarose 
resin (Thermo) while tumbling for 1.5 hours at 4 °C.  The resin was washed twice with 1X PBS 
and the GST-fusion protein was eluted with 6 x 1 mL fractions (50 mM Tris pH 8.0, 10 mM 
glutathione). The resulting yield was 3 mg/L and fusion proteins were >95% pure as estimated 
by SDS–PAGE analysis.  Protein was stored at -80 °C after dialysis in enzyme storage buffer (50 
mM HEPES-KOH pH 7.6. 100 mM KCl, 10 mM MgCl2, 7 mM BME, 30 % glycerol).   
Test of GST-(BRCT)2 Immobilization onto Magnetic Beads. Purified GST-(BRCT)2 fusion 
protein was diluted 1:5 with binding buffer (50 mM Tris-HCl pH 7.8, 150 mM NaCl, 4 mM 
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MgCl2, 0.25 % Triton X-100, 0.1 mg/ml BSA) and incubated with glutathione magnetic beads 
(Thermo) with tumbling for 1 hour at 4 °C.  Any unbound protein was taken as the flow through 
and beads were washed with twice with binding buffer.  Bound protein was eluted with elution 
buffer indicated, and fractions of each step were analysed with a 10 % SDS-PAGE gel. 
Preparation of mRNA Fusions. The in vitro selection protocol has previously been outlined in 
detail
116
 and is described here in brief.  The sequence of the cDNA encoding the mRNA display 
library was: 5’-CTAGCTACCTATAGCCGGTGGTGATGGTGATGGTGGCCTAAGCTACCG 
GAGCCVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNGCACATTTAGCTGT
CCTCCTTACTAAAGTTAACCCTATAGTGAGTCGTATTA-3’.  The library was ordered 
from the HHMI/Keck synthesis facility and was purified by Urea-PAGE.  Following PCR 
amplification of library templates, sequences were verified with TOPO cloning and sequencing.  
An in vitro transcription reaction was followed by Urea-PAGE purification and electroelution to 
obtain purified mRNAs to be used for selection.  The library mRNA was photochemically 
crosslinked to a puromycin linker after annealing followed by exposure to UV irradiation, and 
was then used in translation to produce peptide-mRNA fusions.  A 10 mL scale translation was 
used to generate peptides for the first round of selection.  After translation, fusion formation was 
maximized through the addition of KCl/Mg(OAc)2 as described.
122
  The mRNA peptide fusions 
were bound to Oligo(dT) resin via the poly-A sequence contained in the puromycin linker.  
Peptides were cyclized on the resin using dibromoxylene, and eluted with water.  The cyclization 
reaction was conducted as described.
111c
 This was followed by reverse transcription of the 
mRNA with a primer of the sequence 5’-TTTTTTTTTTTTTTT CTAGCTACCTATAGCCGGT 
GGTGATGGTGATGGTGGCCTAAGC-3’, and Ni-NTA purification of the full-length peptide 
fusions containing a C-terminal hexahistidine tag.  The library was then dialyzed into selection 
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buffer (50 mM Tris-HCl  pH 8, 150 mM NaCl, 4 mM MgCl2, 0.25% Triton X-100) and used in 
the first round of selection.  The yield of peptide fusions after all purification steps was 22 pmol, 
equivalent to 1.3 x 10
13
 peptides.  
Selection.  Prior to the selection, beads containing GST and GST-BRCT were prepared.  GST 
beads:  200 µL of magnetic glutathione beads (Pierce) were washed three times with 1 mL GSH 
beads wash buffer (125 mM Tris-HCl pH 8, 150 mM NaCl).  1 mL of 10 µM GST in GSH beads 
wash buffer was added to the beads and tumbled for 1 hour at 4°C.  The supernatant was then 
discarded and the beads were washed 2x with 1 mL GSH beads wash buffer and 1 x 1 mL 
selection buffer.  GST-BRCT beads:  a separate 400 µL of bead suspension was washed 3x with 
GSH beads wash buffer.  1mL of 10 µM GST-(BRCT)2 was added and tumbled 1 hour at 4°C.  
GST-(BRCT)2 bound beads were washed 2x with GST beads wash buffer and 1x with selection 
buffer.  The previously purified peptide-mRNA fusions were dissolved in 1200 µL selection 
buffer.  Pre-clear: fusions were added to GST bound beads and tumbled 1 hour at 4°C.  
Selection: the supernatant containing the library was transferred from the GST bound beads to 
the GST-(BRCT)2 bound beads.  With an additional three washes, the total volume transferred to 
the GST-(BRCT)2  beads was 1300 µL.  13 µL of 10 mg/mL BSA was also added and the tube 
was tumbled for 1 hour at 4°C.  The beads were washed 3x with 1 mL selection buffer.  Peptide-
fusions were eluted along with the bound protein by the addition of 6 x 100 µL freshly prepared 
GSH elution buffer (250 mM Tris-HCl pH 9, 500 mM NaCl, 100mM L-glutathione reduced 
(Sigma), 1% Triton X-100).  Each addition of elution buffer was allowed to incubate for 5 
minutes.  Portions of selection input, flow through, washes, re-suspended beads and elution 
fractions were quantified by scintillation counting of 
35
S-Met and used to monitor selection 
enrichment.  Elution fractions were combined and dialyzed overnight at 4°C into 0.1% Triton X-
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100 prior to PCR amplification with Library FWD primer: 5’-TAATACGACTCACTAT 
AGGGTTAACTTTAGTAAGGAGGACAGC-3’, and Library REV 5’-CTAGCTACCTATAG 
CCGGTGGTGATGGTGATGGTGGCC-3’ primers.  The amplified cDNA was then transcribed 
and used for the subsequent round of selection.  The scale of the second round of selection was a 
1 mL translation, followed by rounds 3-8 that were started with 500 µL translation reactions.  
Additionally, pre-clearing of the library bound to GST beads was only performed in rounds 1 and 
2.   
cDNA Sequencing.  To analyze the results of the selection, cDNAs were amplified by PCR and 
cloned into the pCR-TOPO vector (TOPO TA Cloning Kit, Invitrogen).   Unnatural amino acids 
were assigned on the basis of the tRNA/AARS pairs responsible for their incorporation into 
peptides.  For DNA and peptide sequence alignments and homology ranking, Jalview Version 2 
was used.
123
  
 
3.7 Summary 
An mRNA display selection with 1.3 x 10
13
 peptide members was selected against a 
recombinant GST fusion of the BRCA (BRCT)2 domain.  After 8 rounds, the surviving peptides’ 
sequences showed 7 sequences occurring multiple times, making up more than 80 % of 
determined sequences. No evidence of cyclization is apparent from the sequences, with an 
UNAA presence biased toward F26 and R1.   
 
Future Directions.  With peptide sequences in hand, it is necessary to rank the peptides by 
affinity as well as to determine how tightly they bind.  Where these peptides bind on the BRCT 
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domain is also important for these peptides to be applied as inhibitors, and will need to be 
investigated.   
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CHAPTER 4. LIFE AFTER SEQUENCING: 
RANKING THE TOP PEPTIDE HITS 
 
 
 
Contributions: 
ERW and David E. Hacker are responsible for peptide synthesis and purification. 
ERW conducted all of the biacore, ITC and FP experiments. 
David E. Hacker is responsible for the MS/MS experiments of cyclized peptides.    
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Chapter 4: Life after Sequencing: Ranking the Top Peptide Hits 
4.1 Introduction 
After 8 rounds of mRNA-display selection against the (BRCT)2 domain of BRCA1, a 
group of 85 sequences were determined.  Nearly 80% of these sequences occurred more than 
once and these 7 sequences were grouped together into families 8.1-8.7, ordered by frequency.  
The D/E-X-X-F motif found in each of these sequences suggests these peptides may bind to the 
same binding pockets as the pS-X-X-F peptides; however, before we can begin to investigate 
such questions it is necessary to first confirm that these peptides bind to the (BRCT)2 domain.  
There are many ways to determine a binding affinity, but before investing too much into 
determining an exact affinity, a quick ranking of these peptides via a radiation spin assay was 
pursued. 
 
4.2 Equilibrium Ultrafiltration Binding Assay 
Although there still isn’t an efficient means of incorporating the arginine analog 
canavanine via solid phase peptide synthesis, synthesis of these peptides should be accessible via 
in vitro translation.  The scale of these reactions is small, but due to the presence of an 
35
S-
methionine it is sufficient for radiation spin assays to determine an approximate Kd of each 
peptide.  This assay, as shown in Figure 4.1, involves the combination of a constant 
concentration of radiolabeled peptide with varying concentrations of GST-(BRCT)2 protein.  
Each sample will then be centrifuged in a 30,000 MWCO spin filter such that approximately half 
of the solution remains in the top portion of the filter and half has been filtered through.  By 
calculating the fraction of peptide bound in each sample, a binding curve can be established  
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Figure 4.1 Equilibrium Ultrafiltration Binding Assay.  Various concentration of  
GST-(BRCT)2 fusion protein is added to concentration of 
35S-labeled peptide.  After 
incubation, the samples are centrifuged in 30,000 MWCO filters so that the sample is 
divided, half filtered through the membrane, and half remaining in the top.  A fraction 
bound can ben calculated in each sample to achieve a binding curve.  
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effectively ranking these 7 peptide families.   
 A cDNA representative of each peptide family was selected to generate the mRNA 
template used for selection.  A second peptide was chosen from family 2 that appeared to have a 
second cysteine, which was called family 8.2c.  All sequences chosen had a full length His-tag.  
The glycerol stocks from sequencing were used to generate purified plasmid which was used in 
PCR amplification of the cDNA insert (Figure 4.2).  In vitro transcription was used to generate 
the mRNA template used for in vitro transcription.   
 The resulting mRNA was used in 250-500 µL scale translation reactions.  The large scale 
reaction included 
35
S-methionine, but a 50 µL reaction was conducted in parallel for 
characterization by MALDI.  Many of the translation reactions suffered from poor yield for 
unknown reason, and even those reactions with sufficient yield to conduct the spin assays were 
not able to be characterized by MALDI.  Typically we can detect as little as 1 pmol after zip-
tipping; however, not a single peptide produced from these mRNA templates was able to be 
characterized even in reactions with yields greater than 1 pmol.  Despite the lack of 
characterization, attempts at the radio-labeled spin assay were conducted with no observed 
binding of any peptide.  At this point it was decided to try to synthesize peptides with solid phase 
peptide synthesis and characterized their binding to the (BRCT)2 domain via surface plasmon 
resonance (SPR).   
 
4.3 Surface Plasmon Resonance 
Being able to synthesize peptides via in vitro translation should have been a rapid method 
of synthesis and characterization; however efficiency was not its only advantage.  As of this  
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Figure 4.2 PCR Amplificaton of Library cDNA.  One cDNA was selected for each of 
the over represented families from the selection.  After 24 rounds of PCR amplification, 
the product was analyzed on a 1 % agarose gel.  A) PCR amplification with primers from 
selection. B) PCR product using shorter primers.
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writing, canavanine in an appropriately protected form for solid phase peptide synthesis (SPPS) 
was not commercially available.  Only one published report of the synthesis of a similar analog 
Fmoc-canavanine(Mtr)-OH exists, and attempts to repeat the reported procedure have been 
unsuccessful.
124
  Although progress is being made toward alternative routes of synthesis, it has 
remained a formidable challenge owing largely to the lability of the O-N bond in procedures 
typically used for Fmoc-arginine(Pbf)-OH as well as the lack of nucleophilicity of the guanidine 
side chain of canavanine.  With synthesis of peptides via in vitro translation an unsuccessful 
endeavor, the decision was made to work toward synthesis via SPPS, with the possibility of 
including arginine in the place of canavanine if necessary.   
At this time it was hoped that we would soon be able to synthesize a suitably protected 
canavanine, thus the peptide characterization began with those peptides without canavanine.  The 
first peptide chosen was peptide 8.3.  Optimistic thinking that cell studies may quickly follow the 
peptide ranking, a nuclear localization sequence (NLS) was added to the C-terminus of the 
peptide making the full peptide sequence: MCNDF26TF26DKNL3NHHGSPKKKRKV, where 
the underlined portion is the sequence of peptide 8.3 and the bold indicates the NLS sequence.  
  It was decided that surface plasmon resonance (SPR) would be a potentially quick 
means of ranking the affinity of the peptides and would also give us kinetic information about 
both the on and off rates of each peptide.  SPR is one of the few techniques that allows 
measurement of the kinetics of binding in real time, which is very powerful in characterizing a 
binding affinity because both kon and koff can be easily determined.  However, because this 
measurement takes place on the surface of a chip surface binding artifacts can obscure the 
solution phase kinetics.   
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  Amine coupling of the GST-(BRCT)2 to the chip surface was tried at first, but this 
technique does not control for orientation of the protein on the chip surface. Direct coupling of a 
protein makes the expected response from peptide binding to the protein more difficult to 
estimate.  Due to the multiple protein orientations, peptides will not be able to bind to every 
protein.  When peptide binds to the protein on the surface, the amount of peptide bound can be 
correlated to the response units (RU) measured by the detector with the following equation.   
    [4.1] 
where Rmax is the the preducted total response of an assay in RU; Rligand is the response of the 
bound protein in RU; the stoichiometry is equal to 1; MWligand is the molecular wieght of the 
peptide, 2939 amu; and WMprotein fusion is the molecular weight of the GST-(BRCT)2 protein 
bound to the surface 51.2 kDa.  Although directly coupling protein to the surface may 
underestmate the maximum observable response from peptide binding, a more important 
disadvantage of this technique is the inability to regenerate the bound peptide.  Peptides are only 
stable for a certain period of time, and it is advantageous to use fresh fusion peptide for each 
analysis. 
By switching to a configuration, shown in Figure 4.3, where an anti-GST antibody was 
first coupled to the chip surface, the RU could accurately be predicted, and the fusion protein 
could be freshly added for each experiment leading to more accurate analysis.  From initial 
experiments it was found that the RU resulting from peptide biding was orders of magnitude 
greater than the expected RU.  This likely indicates that the peptide is non-specifically binding to 
the chip surface.  The surface of the chip is a negatively charged dextran, so it is not surprising 
that the positively charged NLS sequence would bind to the chip surface.  This was confirmed 
when a series of samples were run at various salt concentrations (Figure 4.4), where salt  
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Figrue 4.3 SPR Experiment with α-GST Antibody.  First a α-GST antibody is 
covalently coupled to the dextran coated chip using standard amine coupling 
chemistry.  The (BRCT)2-GST fusion is then immobilized on the chip via interaction 
with the antibody.  Various concentrations of peptide are then flowed over the chip 
and the resulting response is recorded.
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Figure 4.4 SPR with Nuclear Localization Sequence.  The above trace shows the 
response units recorded for peptide samples in buffer containing different salt 
concentrations binding to the immobilized GST-(BRCT)2.  Below is the sequence 
of the peptide used in this study with the charges indicated.  
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concentrations as high as 0.5 M NaCl were able to able to interrupt the non-specific interactions 
bringing the RU down to the expected range.  Although, there are other chip surfaces, such as an 
amine based chip that could also eliminate the non-specific interaction, it may have been just as 
simple to re-synthesize the peptide without the NLS which was likely causing the problem.  It 
was while making this decision, the instrument developed technical difficulties not readily 
remedied, and the decision was made to pursue alternative means of peptide characterization.   
 
4.4 Isothermal Titration Calorimetry 
 Because Isothermal Titration Calorimetry (ITC) is a solution based technique, the 
presence of a NLS in theory should not interfere with characterization of peptide binding.  The 
NLS may alter the affinity of the peptide, but the same surface effects seen with SPR should not 
be an issue.  There was a significant learning curve when using ITC that can be mostly summed 
up into a single concept: the ITC is a sensitive instrument and must be very clean to get accurate 
results.  This however, is often easier said than done, and in the case of our peptides this learning 
curve was complicated due to the low affinity of the peptides.  With ITC, there is a range of 
affinities that are optimal for analysis, which can be defined by the following equation 
c     [M]        [4.2] 
where c is the Wiseman c parameter, n is the molar ratio, Ka is the association constant, and [M]t 
is the total protein concentration.
97
   
The optimal range for any ITC analysis is a c value between 10 and 100.  At high c 
values, the titration curve becomes too steep, and at low c values the curve becomes a shallow 
almost linear slope.  Both of these scenarios make accurate data analysis difficult, if not 
impossible.  As can be seen in the equation above, c is dependent up on n (reaction 
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stoichiometry) and Ka (the association constant) which are inherent to the interaction under study 
and therefore cannot be altered.  This leaves the concentration of protein, [M]t, as the only 
parameter that can be manipulated to produce an experiment with an optimal c value.  For high 
affinity inhibitors, the limitation of protein dilution to lower the c value is dependent upon the 
amount of heat than can be measure in dilute solutions.  For low affinity interactions, achieving 
high protein concentration is limited by protein solubility.  The GST-(BRCT)2 fusion protein that 
was used for selection worked very well at the low concentrations needed for immobilization to 
magnetic beads, or to the surface of an SPR chip, but for ITC it was necessary to have a protein 
concentration as high as possible.  Solubility of the GST-(BRCT)2 fusion became a significant 
problem during attempts to achieve the high concentrations needed for ITC analysis.  
Precipitation was observed during the concentrating process as well as during the actual ITC 
analysis.  One means of explanation for this observation is because GST exists as a dimer, and 
the BRCA1 (BRCT)2 domain that displays weak homodimerization.  At low concentrations, 
solubility was not a significant problem, but as the concentration increased for ITC analysis, 
perhaps these two dimerizing proteins formed a polymer resulting in significant precipitation.  
Despite these hurdles, reasonably successful ITC analysis was achieved for 4 peptides (Figure 
4.5).  The only peptide with a discernable sigmoidal curve is peptide 8.3 D4pS.  The plots that do 
not appear sigmoidal have high error as they fall below the recommended c value for ITC 
analysis.   
 
4.5 MS/MS Analysis of Peptide Cyclization 
While initial SPR and ITC studies were being conducted with peptide 3, DEH began 
investigating what product was formed in the cyclization reaction with these peptides that did not  
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Figure 4.5 Initial ITC Data with NLS Peptides. Shown here are the initial ITC 
curves obtain for four peptides containing nuclear localization sequences (NLS).  
94 
 
have a second cysteine.  It was a bit surprising that none of the sequences contained a second 
cysteine, and it was unclear the fate of mono-Cys peptides.  A peptide of the sequence 
MCNDF26TF26DKNL3NHHGSPKKKRKV was subject to cyclization and analyzed by ESI-
MS/MS.  The results of this analysis indicate cyclization is limited to an interaction between the 
peptide’s N-terminal Met and Cys, forming a cyclic sulfonium group (Figure 4.6). 
 
4.6 Fluorescence Polarization 
After running into technical difficulties with the radiolabeled spin assay, SPR and ITC 
analysis of peptides, it was determined that a fluorescence polarization (FP) assay might be the 
best alternative to rank the peptides from selection.  Like ITC, FP has some limitations with 
regard to the range of binding affinities it can accurately measure.  ITC is limited by its c value; 
however, FP is often not suitable to measure low affinity proteins due to the high protein 
concentrations needed to produce a full binding curve.  In a typical assay, a fluorescently 
labelled peptide is kept at a constant concentration with increasing concentration of protein.  At 
the high concentrations needed to examine low binding affinities, protein solubility and 
aggregation begin to interfere with analysis due to non-specific light scattering that exists in 
samples containing aggregates or with higher viscosity.  This rationale combined with the 
simplicity of synthesizing a single fluorescently-labelled inhibitor instead of labelling each 
peptide under study made a competition study an ideal means to rank the peptides. Although this 
will not directly determine a binding affinity in terms of Kd, it will allow for determination of an 
IC50 with respect to the known inhibitor.  In other words, a competitive FP study will determine 
the half maximal concentration of our competing peptides that can successfully prevent the know 
inhibitor from binding.   
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Figure 4.6 Proposed Cyclization Structure. This structure was proposed based on 
MS/MS data of library peptide 8.3 cyclized with dibromoxylene.  In the absence of 
a second cysteine, it is thought that cyclization is occurring between the N-terminal 
Met-Cys producing the sulfonium ion shown.    
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FAM-β-A-pSPTF-NH2 is a known BRCA1 (BRCT)2 binding peptide that has been used  
previously in FP competition assays.
108
  All competitor peptides from the library were generated 
via SPPS and purified by HPLC, with verification by MALDI (See Appendix I).  As of this 
writing, protected canavanine suitable for SPPS has still not been successfully synthesized, so 
each of the peptides characterized by FP has arginine where canavanine was present in the 
peptide sequence.  The major difference between the two molecules is their side chain pKas (Arg 
pKa = 12.5, canavanine pKa = 7.0).
125
   
Initial fluorescence polarization competition assays were conducted with representative 
peptides in their full length, un-cyclized form.  All assays utilized a thioredoxin (TR) fusion 
protein, TR-(BRCT)2, which has superior solubility to the GST-(BRCT)2 fusion.  SDS-PAGE 
analysis of this proteins purity can be found in Figure 4.7.  All seven peptides were tested in their 
linear forms, and five of them were tested as cyclization products as solubility and stability 
allowed.  The curves resulting from this analysis can be found in Appendix II.  The IC50 values 
determined for all twelve peptides can be seen in Table 4.1.  Linear peptide 8.6 had the highest 
binding affinity with an IC50 of 10.5 µM, binding twice as strongly as peptides 8.1 and 8.5, and 
more than five-fold more strongly than any other peptide tested.  The effect of cyclization had a 
negative impact on affinity except in the case of peptide 8.1 where there was a neutral effect on 
binding.   
 
4.7 Discussion 
In the selection sequences, no second cysteines were found in the random region, but 
MS/MS analysis of a cyclized peptide revealed the presence of dibromoxylene cyclization 
between the N-terminal Met-Cys.  It is possible that the reactive sulfonium ion formed in  
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Figure 4.7 SDS-PAGE Analysis of Purified Thioredoxin-(BRCT)2 Fusion 
Protein.  Analysis of the purified BRCT fusions by SDS-PAGE and staining 
with Coomassie Blue shows proteins estimated to be >95% pure.  The 
expected mass of TR-(BRCT)2 is 42.9 kDa.
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Peptide Sequence IC50 (µM)
8.6 MCTIDFDEYRFRKT 10 ± 1
8.6c MCTIDFDEYRFRKT 24 ± 2
8.1c MCNDFIFRRSTFRA 25 ± 2
8.1 MCNDFIFRRSTFRA 24 ± 2
8.5 MCYDFDTTNDHTFI 26 ± 2
8.2 MCSDFIFSRRTYTF 49 ± 5
8.4 MCHNDFAFAKTSLY 56 ± 4
8.7 MCDFQFRKPSTTIY 56 ± 6
8.3 MCNDFTFDKNLNHH 99 ± 8
8.7c MCDFQFRKPSTTIY 122 ± 9
8.4c MCHNDFAFAKTSLY 125 ± 12
8.3c MCNDFTFDKNLNHH 142 ± 15
Table 4.1 Ranking of Peptides from Selection.  The linear form of all seven 
peptides and the cyclized form of five, were tested in a competition assay with 
FAM-β-A-pSPTF, a peptide known to bind the (BRCT)2 domain.  
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cyclization could result in a covalent linkage upon binding to the protein if the right 
functional groups were near; however, our Biacore data did not support a covalent mechanism.  
The seven peptide families in both linear and cyclized forms were eventually ranked by 
their binding affinity by FP after technical hurdles were uncovered with other techniques.  
Comparison of the binding affinity of linear and cyclized peptides with FP showed that 
cyclization had a negative effect on binding affinity in all cases except peptide 8.1 where the 
affect was neutral.  Since 40% of the library should have had a second cysteine somewhere in the 
random region, and none of these were selected seems to suggest that the (BRCT)2 domain 
prefers a more extended binding motif.  The question of whether the entire length of these 
peptides is required to bind remains unanswered, but suggests that the full length may be 
necessary, or that the presence of cyclization with a second cysteine actually produced peptides 
in unfavourable binding confirmations.  
Although each of the techniques employed here are suitable for ranking the peptides from 
selection based on their approximate affinities, technical challenges were a significant hurdle in 
this endeavor.  The radiation spin assay could have allowed us to easily rank the peptides as well 
as to examine the effects of UNAA compared to the all-natural analogs.  The frequently poor 
yields obtained from these reactions as well as the inability to characterize these peptides by 
MALDI-TOF led us to pursue techniques using peptides made with SPPS.  Initially peptide 8.3 
(which was chosen due to its lack of canavanine which was not able to be incorporated in the 
solid phase) was examined by SPR in both its linear and cyclized state with the addition of an 
NLS.  In the end, the positive charge of the NLS led to significant non-specific interaction with 
the negatively charged SPR chip.  By the time this was confirmed, technical difficulties with the 
instrumentation led us to pursue other avenues of analysis. 
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 Testing these same peptides with ITC led to less than optimal results partially due to 
technical problems with instrument maintenance and GST-(BRCT)2 solubility, but also because 
these peptides have low enough affinity, perhaps affected by the presence of the NLS, that they 
are outside the optimal range of analysis for ITC.  It was then decided that all 7 peptides should 
be synthesized on the solid phase without an NLS or any other modification with arginine in the 
place of canavanine.  These peptides in their linear and cyclized forms were ranked by IC50 
through a competitive FP assay against a known inhibitor FAM-β-A-pSPTF.  The FP curves 
collected can be found in the Appendix II.  The highest affinity peptide was fond to be the linear 
form of peptide 8.6.  This peptide will be the subject of further investigation into how this 
peptide binds to the (BRCT)2 domain. 
Unfortunately, not being able incorporate the canavanine that was present in selection 
leaves many questions unanswered.  Linear peptide 8.6 had the highest affinity with an IC50 of 
10.5 µM.  Would this have been lower if canavanine were in place of arginine?  Inclusion of 
arginine means that this residue has a positive charge where none was present during selection, 
as well as a carbon where an oxygen would be which could alter potential hydrogen bonding 
interactions.  Other arginine analogs such as citrulline could be used to approximate the effect of 
canavanine’s neutral charge, but the only current means to investigate peptides with canavanine 
is to synthesize them with in vitro translation. 
 
4.8 Experimental 
Generation of peptides with in vitro translation. Glyerol stocks from selection were grown up 
overnight in 1ml LB containing kanamycin.  The next day the cultures were removed from the 
shaker and cells were collected via centrifugation.  The plasmids were purified with Qiagen 
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miniprep.  PCR amplification was conducted with the same primers used for selection with serial 
dilutions of the template plasmid with 24 rounds of amplification.  The primers used for 
amplification of families, 1, 4, 5, 6, and 7 had the following sequences: FWD TAATACGACTC 
ACTATAGGGTTAACTTTAGTAAG, REV CTAGCTACCTATAGCCGGTGGTG.  A 500 uL 
in vitro transcription reaction was set up for each PCR product as previously described.
103
  The 
resulting mRNAs were purified by urea-SDS-PAGE and electroelution followed by ethanol 
precipitation.  500 uL scale in vitro translation reactions were conducted with each mRNA 
template as previously described.
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Radiation Spin Assay.  A constant concentration of 
35
S-methionine containing peptide from in 
vitro translation reactions was incubated with different concentrations of GST-(BRCT)2 fusion 
protein in 200 L selection buffer (50 mM Tris-HCl  pH 8, 150 mM NaCl, 4 mM MgCl2, 0.25% 
Triton X-100) while tumbling for 5, 20, 60 and 120 minutes at 4C in a YM-30 filter. After 
incubation samples were spun at 12200 rpm for 75 seconds until approximately half of the 
volume had been filtered into the bottom collection chamber.  The radioactivity in the top and 
bottom chamber was determined by removing 75 L from each.  From this the total peptide 
(“top”) and free peptide (“bottom”) concentrations were used to calculate the fraction of peptide 
bound from the formula fa = [bound peptide]/[total peptide], where  [bound peptide] is the 
concentration of peptide bound to the GST-(BRCT)2 fusion protein and [total peptide] is the total 
peptide concentration, by substituting top-bottom for [bound peptide] and top for [total peptide]. 
  
Peptide synthesis. The peptides were synthesized using a Liberty Automated Microwave 
Peptide Synthesizer (CEM). The peptides were synthesized on Fmoc-PAL-PEG-PS Resin 
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(Applied Biosystems) using N-α-Fmoc-protected amino acids (CEM or AAPPTEC) or unnatural 
N-α-Fmoc protected amino acids (Chem Impex). After each coupling step a capping step was 
performed using 20% acetic anhydride (Fisher Certified ACS). The peptides were cleaved from 
the resin using trifluoracetic acid (TFA) (Chem Impex)/TIS (Sigma)/DODT (Sigma)/water 
(92.5:2.5:2.5:2.5) with incubation at room temperature for 3 hours, and the resin was filtered off.  
The filtrate containing the crude peptides was precipitated with cold ether, and collected by 
centrifugation.  The supernatant was discarded and the peptide was dissolved in CH3CN (Fisher 
HPLC Grade) and water with 10% acetic acid (Fisher certified ACS PLUS) (1:1) followed by 
freezing and lyophilization.  The peptides were then purified by reverse phase HPLC using a 
Shimadzu Prominence system with a Vydac (218TP C18 5μ) column with 0.1% TFA in water 
(A) and CH3CN (B) as the mobile phase with monitoring at 215nm or 264nm.  A typical gradient 
was 10-100% B over 30 minutes, but was adjusted for each peptide.  MS data was collected 
using a Micromass MALDI-R spectrometer. 
MALDI-TOF Analysis.  HPLC fractions were prepared for analysis by 1:1 dilution in a 
1:0.99:0.01 CH3CN:H2O:TFA solution containing 10 mg/mL α-cyano-4-hydroxy-cinnamic acid 
(CHCA).  After spotting on the sample plate, samples were allowed to co-crystallize by slow 
evaporation at rt.  Samples resulting from translation reactions were desalted and concentrated 
with ZipTipC18 Pipette Tips (Millipore) according to the manufacturer’s protocol.   
Peptide Cyclization with α-α’-dibromo-m-xylene:   A 50 mL oven-dried flask was charged 
with water (19.34 mL) and acetonitrile (5.28 mL) and was deoxygenated by bubbling Argon for 
10 min. Then 200 mM ammonium bicarbonate (3.5 mL, pH 8.4), tris-carboxyethylphosphine 
(TCEP) (2.0 mg, 7.0 μmol) in 3.5 mL water and peptide (10 mg, 3.5 μmol) were added and the 
reaction was kept under argon. After 30 min, α-α’-dibromo-m-xylene linker (10.2 mg, 38.6 
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μmol) was added as a solution in 3.5 mL of acetonitrile. The reaction was incubated at rt and 
monitored by MALDI-TOF. After 2 h, β-mercaptoethanol (BME) (13.7 mg, 176 μmol) or 
dithiothreitol (DTT) (27.1 mg, 176 μmol) was added to quench unreacted linker, which 
serendipitously led to formation of peptide-linker-BME (or DTT) adducts upon concentration 
during lyophilization. Omission of the quench step resulted in the desired α-α’-dibromo-m-
xylene cyclized peptide product. The reaction was then frozen and lyophilized. The resulting 
white powder was dissolved in 25% acetonitrile and purified by reverse phase semi-preparative 
HPLC under the following conditions. Column: Vydac 218TP52210 22 x 100 mm: Flow rate: 10 
mL/min: Solvents: A=water/0.1% TFA, B=acetonitrile/0.1% TFA): Gradient: 10 min at 10% B, 
30 min at 10-55% B. Injection occurred at 5 min. 4.8 mg (1.63 μmol, 47%)  of pure, unquenched 
product was recovered. 
Determination of Protein and Peptide Concentrations.  All protein and peptide concentrations 
were determined using their UV absorbance at 280 nm according to the method of Gill and von 
Hippel 
126
.  Extinction coefficients: GST-(BRCT)2 = 76810 M
-1
cm
-1
; TR-(BRCT)2 = 50070 M
-
1
cm
-1
; FAM = 75800 M
-1
cm
-1
; Peptides = 1280 M
-1
cm
-1
 (each contains a single Tyr).   
Surface Plasmon Resonance. All experiments were performed at 25 °C on a Biacore 2000 
instrument (GE Healthcare).  Immobilization of either GST-(BRCT)2 fusion or α-GST antibody 
was achieved via amine coupling to a CM5 chip (GE Healthcare) per the manufacturer’s 
instructions (Amine coupling kit, GST capture kit, GE Healthcare).  Peptides were diluted in 
HBS-EP running buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% 
Surfactant P20) with the adjusted NaCl concentrations as indicated. 
 
Isothermal Titration Calorimetry. ITC experiments were performed on an ITC200 calorimeter 
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(Microcal Inc.) in 300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4.  Experiments were 
carried out by titration of 200-400 µM peptide in the syringe into 20-30 µM TR-BRCT protein in 
the sample cell. The cell was thermostated at 25 °C and the syringe was stirred at 400 rpm. Each 
titration consisted of 20 injections of 2 µl except for the first addition which was only 0.5 µL.  
This first data point was deleted prior to data analysis.  Control experiments consisted of titration 
of peptide into buffer alone to determine the heat of dilution which was subtracted from the data 
collected from the peptide into protein titration.  The resulting data was fitted using a one-set 
binding-site model analysis using Origin 7 software (Microcal Inc.) to obtain binding 
stoichiometry (N), association constant (Ka), change in enthalpy (ΔH).  ΔG and ΔS were 
calculated with the following equations: ΔG = -RT*ln(Ka) and ΔS = (ΔH – ΔG)/T.   
Cloning and Protein Expression.  To prepare an N-terminal thioredoxin fusion with C-terminal 
His-tag (TR-BRCT).  The pGEX-4T-1 vector containing the BRCA1 (BRCT)2 domain (amino 
acids 1646-1859)
119
 previously described (Chapter 3) was digested with BamHI and XhoI and 
ligated into the modified pET32a.
127
  After transformation into Rosetta 2(DE3) strain of E. coli, 
cells were induced using IPTG and expressed overnight at 18 °C. The recombinant protein was 
purified on FPLC using nickel affinity chromatography with Chelating Sepharose Fast Flow 
resin (GE Healthcare) and elution with a gradient of imidazole (50 mM phosphate pH 8.0, 300 
mM NaCl, 25 mM imidazole wash, 250 mM imidazole elute) followed by chromatographic 
isolation by size exclusion chromatography with HiLoad 26/60 Superdex 75 prep grade resin 
(GE healthcare) in Buffer A (300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4).  The 
resulting fusion proteins had a yield of 20 mg/L and were >95% pure as estimated by SDS–
PAGE analysis.  Proteins were stored at -80 °C after dialysis in 1L enzyme storage buffer (50 
mM HEPES-KOH pH 7.6. 100 mM KCl, 10 mM MgCl2, 7 mM BME, 30 % glycerol).   
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Determination of IC50 with Fluorescence Polarization.  The indicated amounts of competing 
peptide were added to a total of 150 µL containing 2.5 µM TR-(BRCT)2 and 20 nM FAM-β-Ala-
pSPTF in 300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4.  The samples were incubated 
at room temperature for 2 hours.  The samples were then analyzed in a 100 µL quartz 
fluorescence cuvette using a Cary Eclipse Fluorescence Spectrophotometer (Varian Instruments) 
with polarizing lens attachment.  The G-factor was experimentally determined with sample 
containing 20 nM FAM-β-Ala-pSPTF in the same buffer.  Anisotropy values were automatically 
calculated by the accompanying Advance Reads software.   After plotting anisotropy versus 
peptide concentration, an IC50 was determined as the peptide concentration at which 50% of the 
FAM-β-Ala-pSPTF was bound by fitting to the four parameter logistic equation using SigmaPlot 
11.  
 
4.9 Summary 
 On the road to ranking the top 7 hits from the library selection many technical hurdles 
were encountered.  After attempting radiation spin assay, SPR, and ITC, finally FP was used to 
rank the peptides in a competition assay with a phopsphoserine containing peptide known to bind 
to the BRCA1 (BRCT)2 domain.   
Future Directions: Now that an initial ranking has been achieved, there are many more 
questions remaining with regard to the highest affinity peptide: linear peptide 8.6.  Whether or 
not the full length of the peptide is necessary will be investigated as well as mutational analysis 
of individual amino acids.  The presence of an E-X-X-F motif of this peptide suggests it may 
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bind in the same pockets as the pS-X-X-F motif, and the importance of these amino acids can be 
partially addressed through alanine mutations.  
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CHAPTER 5. WHERE’S THE PHOSPHATE?: INVESTIGATION OF PEPTIDE 8.6 
BINDING MECHANISM THROUGH MUTATIONAL ANALYSIS 
 
 
 
108 
 
5.1 Introduction 
The ultimate goal for this project was to discover a non-phosphorylated peptide that binds 
to the (BRCT)2 domain of BRCA1 in the same location as proteins known to interact with this 
domain.  The presence of our D/E-X-X-F motif in each peptide is an encouraging indication that 
the selected peptides are in fact competitive inhibitors due to the analogous pS-X-X-F motif that 
is currently thought to be necessary for proteins binding to this domain.  Presence of a similar 
motif does not guarantee binding and needs further testing to support this hypothesis.  The focus 
of this chapter is mutational studies with the aim of understanding how the highest affinity 
peptide 8.6 is binding to the (BRCT)2 domain, as well as attempts to improve up on the affinity 
of this peptide. 
 
5.2 Examination of Peptide 8.6 Truncation 
With linear peptide 8.6 being the highest affinity peptide from selection it was decided to 
focus all further efforts on this peptide.  A series of truncated peptides were made and their 
affinities were compared to linear peptide 8.6 via the same fluorescence polarization assay.  The 
results from these studies can be found in Table 5.1.  It was first investigated to what extent the 
putative core amino acid, DEYRF and FDEYRF could bind to the (BRCT)2 domain, but these 
peptides had little to no binding to the protein.  This provides evidence that amino acids outside 
the core tetrapeptide provide significant binding interactions, which is in contrast to previous 
phosphoserine-containing peptide binders.
109
  To determine the contribution of both termini of 
the peptide we made a few truncation mutants.  Further truncation mutants showed that removal 
of the C-terminal RKT led to a small 2-fold increase in IC50 while N-terminal truncation led to a  
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Peptide Sequence IC50 (µM)
8.6 MCTIDFDEYRFRKT 10.5 ± 1.0
8.6 7-11 DEYRF >500
8.6 6-11 FDEYRF >500
8.6 1-11 MCTIDFDEYRF 23.8 ± 1.9
8.6 7-14 DEYRFRKT 274 ± 59
-MC TIDFDEYRFRKT 25.5 ± 5.4
Table 5.1 Truncation Analysis of Peptide 8.6. Peptide 8.6 was incrementally 
truncated to investigate whether the full length of the peptide was necessary to 
achieve its highest binding affinity.  These peptides were tested via an FP 
competition assay and the IC50s resulting are shown here.  4-F-phenylalanine is 
indicated by red lettering.
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25-fold increase.  Therefore the N-terminal 6 amino acids are more important for binding than 
the C-terminal “RKT.” Another peptide was made to investigate the presence of the N-terminal 
fixed  
Met-Cys.  As part of the non-random region, this was not optimized from the library other than 
its position relative to the D/E-X-X-F motif.  Removal of these amino acids resulted in a two-
fold decrease in affinity which is the same effect as “blocking” these amino acids with 
cyclization.  This was yet another indication that the full length is necessary to achieve the 
highest affinity.    
 
5.3 Mutational Analysis of Peptide 8.6 
For results of FP analysis, see Table 5.2.  To investigate whether the EYRF motif is 
binding in the same manner as the pS-X-X-F motif in other known peptides we mutated the Phe 
to Ala (F11A) and changed the Glu to Ala (E8A). Both mutants showed a dramatic increase in 
the IC50 value, highlighting their importance for binding.  It is interesting that the individual 
amino acids in this motif are necessary yet not sufficient for binding.     
If the elimination of the glutamic acid had such a dramatic decrease in binding, then what 
effect would the incorporation of a phosphoserine have?  In previous studies the mutation of a 
phosphoserine to the phosphomimetic amino acids glutamic and aspartic acid has led to a several 
order of magnitude decrease in binding if not complete elimination of binding.
128
  Because of 
these results we were surprised that 8.6 E8pS peptide had only a three-fold increase in binding 
affinity.  Because of the small increase, it was hypothesized that the presence of phosphoserine 
perhaps changed the mechanism of binding.  The truncation studies showed that the N-terminal 
MCTID was important for peptide binding, and this same truncated peptide with an EpS  
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Peptide Sequence IC50 (µM)
8.6 MCTIDFDEYRFRKT 10.5 ± 1.0
8.6 F11A MCTIDFDEYRARKT 356 ± 35
8.6 E8pS MCTIDFDpSYRFRKT 3.45 ± 0.34
8.6 E8A MCTIDFDAYRFRKT > 300
8.6 E8pS 8-14 pSYRFRKT 2.73 ± 0.09
8.6 All Natural MCTIDFDEYRFRKT 4.54 ± 0.22
Table 5.2 Mutational Analysis of Peptide 8.6. In attempt to investigate 
whether peptide 8.6 binds in the same manner as native (BRCT)2 domain 
binders, peptides with key mutations were analyzed via an FP competition 
assay.  The results are shown here. 4-F-phenylalanine is indicated by red 
lettering.
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substitution had an even lower IC50 than the full length 8.6 E8pS peptide.  Could the presence of 
the phosphate change the way this peptide binds?  Additionally an all-natural (AN) version of 
Peptide 8.6 was tested to probe the effect of the 4-fluoro-Phe.  Unfortunately canavanine was 
unable to be incorporated in these peptides, so its importance is currently unable to be examined.  
Some previous investigations of other hydrophobic amino acid substitutions for phenylalalanine 
in the pS-X-X-F motif indicate that this hydrophibic binding pocket is quite selective and no 
analogs were found to be superior to phenylalanine.
128b
  Although none of the phenylalanine 
analogs tested was as small of a modification as a single fluorine, the FP data from AN 8.6 
indicates elimination of the two fluorines resulted in better binding.   
 
5.4 Hybridization of Peptides 8.1 and 8.6 
 Given that the random region is only twelve amino acids in length, one can’t help but to 
wonder what might have been found if the random region had been longer.  The study of 
truncated peptide 8.6 seems to indicate than the extended linear confirmation is necessary for 
high affinity binding.  Not every peptide has the same placement of the D/E-X-X-F domain, so is 
it possible to generate a higher affinity peptide than any found in selection by hybridizing our 
highest affinity peptides through mixing and matching those amino acids outside the core 
domain?   
Peptides 8.1 and 8.6 are the two highest affinity peptides from the selection and these 
peptides have significantly different placement of the E/D-X-X-F domain.  Combining the long 
N-terminal portion and core of peptide 8.6 that has shown to be important with the long C-
terminal portion of peptide 8.1 did not result in a peptide with higher affinity than peptide 8.6  
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(See Table 5.3).  Although a disappointing result, it also seems likely that the length of this 
peptide (18 amino acids) may create additional contacts, but also increases the entropic cost paid 
in binding.  Entropic cost in mind, another hybrid peptide was created where the shorter N-
terminus of peptide 8.1 was combined with the core and shorter C-terminus of peptide 8.6.  Since 
the  N-terminus of peptide 8.6 was shown to be critical it was surprising that this short peptide 
was only weaker by a factor of 2-3.  This may suggest that the N-terminal MCN of peptide 8.1 
makes important contacts with the (BRCT)2 domain.  In addition to the D/E-X-X-F motif, the 
majority of the peptide families also have a threonine somewhere in the C-terminal sequence.  
Could the hybridization of the N-terminal portion of peptides 8.1 and 8.6 result in a higher 
affinity peptide?  The N-terminal RKT was added to the end of hybrid peptide 2, but this actually 
resulted in a slight decrease in binding affinity rather than an increase.   
Mixing and matching of peptide pieces outside the core domain did not prove successful 
in producing higher affinity peptides, but questions remained about the effect of amino acids in 
the core domain.  Instead of substituting any individual core domain for another, these were 
investigated incrementally.  Comparisons were again made between peptides 8.6 and 8.1 because 
they were the highest affinity peptides, but peptide 8.1 also contains the core domain that 
occurred the largest number of times in selection since the DFIF motif found in 8.1 is also the 
core domain of 8.2.  First, an E8D mutation was made of peptide 8.6 to compare the two 
phosphoserine analogs, but this mutation was not beneficial indicating preference of the glutamic 
acid.  The difference between the core domains primarily lies in the amino acids selected for the 
“X-X” portion of the core domain.  A substitution of the FI from peptide 8.1 for the YR in 
peptide 8.6 also had a minimally negative effect providing further evidence that the core domains 
are not completely interchangeable.  Another interesting observation in the sequence of peptide  
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Peptide Sequence IC50 (µM)
8.6 All Natural MCTIDFDEYRFRKT 4.5 ± 0.2
8.1, 8.6 Hybrid MCTIDFDEYRFRRSTFRA 18.6 ± 0.8
8.6 E8D MCTIDFDDYRFRKT 9.6 ± 0.5
8.6 Y9F, R10I MCTIDFDEFIFRKT 7.0 ± 0.4
8.6 D7N MCTIDFNEYRFRKT 5.6 ± 0.1
8.1, 8.6 Hybrid 2 MCNEYRFRKT 12.7 ± 2.0
8.1, 8.6 Hybrid 3 MCNEYRFRKTFRA 14.5 ± 2.3
Table 5.3 Analysis of Hybridized Peptides. Six peptides were synthesized that 
were hybridized sequences of peptide 8.1 and 8.6.  These peptides were 
subjected to an FP competition assay and the resulting IC50 are shown in this 
table.
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8.1 is the presence of an asparagine -1 from the DFIF.  This D7N mutation was tested and was 
found to be a nearly neutral mutation.  Although the D7N mutation may not have made an 
improvement of peptide affinity, but it did show an improvement in solubility, which may be 
useful in later studies.   
 
5.5 Examination of Highest Affinity Peptides by ITC 
Ranking peptides via their IC50 values proved useful for comparison between peptides; 
however, to compare these peptides to other known binders determination of a Kd is necessary.  
Another point to consider is that it is well known that IC50 values approaching the Kd of a 
fluorescent ligand (in our case 2.3 µM)
108
 are obscured by the fluorescent ligand’s intrinsic 
affinity,
129
 so comparisons between ligands with IC50 values approaching the Kd of the 
fluorescent ligand are not reliably quantitative.   
Further characterization of peptides (8.6, AN, 8.6 E8pS, and 8.6 8-11 8EpS) by ITC was 
conducted (Figure 5.1).  The relative ranking of the binding affinity of the three peptides is 
roughly the same as that determined by FP (E8pS > AN > 8.6).  The relative entropic and 
enthalpic contributions to binding were also determined (Table 5.4, Figure 5.2). The binding of 
all three peptides is driven by large, negative ΔH values.  Surprisingly, the glutamic acid-
containing peptides from our libraries have more negative ΔH values than E8pS.  One potential 
rationale for this increase in ΔH is that the glutamic acid containing peptides form additional 
contacts (presumably at the N-terminus) with the protein which result in the more favorable 
value.  This pattern holds true except for the E8pS 8-14 peptide that actually has a larger 
negative ΔH than the full length E8pS peptide. 
The binding of all four peptides have negative ΔS values.  The entropic term of binding is  
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Figure 5.1 ITC Analysis of Highest Affinity Peptides. The curves shown 
above are the ITC curves collected for four of the highest affinity peptides 
uncovered from selection and mutation of peptide 8.6.
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Figure 5.2 Inhibition of (BRCT)2 and CtIP in Interaction in Cell Lysate.  A 
pull down study was conducted in which CtIP-myc was over expressed in cell 
lysate and bound to immobilized GST-(BRCT)2 on agarose.  This interaction 
was inhibited with increasing concentrations of AN peptide 8.6.  
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correspondingly less favorable for the peptides containing Glu vs. pSer except in the 
E8pS 8-14 peptide.  Before testing of the truncated pSer peptide, it was hypothesized that the Glu 
peptides are gaining additional N-terminal contacts not found in E8pS.  These additional contacts 
would be thought to increase the entropic cost of binding; however, this model does not fit given 
the increased entropy of binding found in the shorter E8pS 8-14 peptide. 
Finally, it is interesting that the replacement of two fluorines with two hydrogens (8.6 to 
AN) results in a significant increase in ΔS.  This is the opposite of what is typically observed 
with fluorine substitutions, since the more hydrophobic fluorinated molecules typically have 
more favorable entropy due to desolvation of their increased hydrophobic surface.
130
 Although 
this could be explained by different solution structure preferences of the two peptides, we think it 
is more likely that the increase in entropy results from more flexibility in the binding of Phe vs. 
the slightly more sterically demanding 4-F-Phe.  We are currently pursuing crystallographic 
studies to investigate these hypotheses.  
 
5.6 Inhibition of CtIP-BRCA1 Interaction in Cell Lysate 
In order to assess the ability of the highest affinity non-phosphorylated peptide (AN) to 
inhibit protein-protein interactions in cell lysates, a known BRCA1 (BRCT)2 binding partner 
phospho-CtIP-myc
131
  was overexpressed in 293T cells and captured with purified GST-
(BRCT)2 fusion in the presence of varying concentrations of the peptide.  Proteins were 
separated by SDS-PAGE and analysed via western blotting (Figure 5.3).  A dose-dependent 
inhibition of the CtIP-BRCT complex was observed, resulting in near complete abrogation of 
this interaction at 50 µM.   
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5.7 Discussion 
Mutational Analysis of Peptide 8.6. Truncation of peptide 8.6 down to its core DEYRF 
domain resulted in nearly complete abolishment of binding.  No truncation mutations were found 
that maintained an IC50 as low as the full length peptide, but deletions of the N-terminal and C-
terminal regions outside of the core domain showed that overall the N-terminal region of the 
peptide plays a large role in the interaction.  The pSer and Phe of native peptides are generally 
regarded as being necessary and sufficient for binding to the (BRCT)2 domain.  Therefore it 
stands to reason that if our D/E-X-X-F peptides are biding in the same pockets, elimination of 
the key E and F via alanine mutation might also abrogate the interaction.   
Despite the inability of the core domain to bind alone, these alanine mutations had a 
significant impact on binding affinity indicating they are playing a very important role.  It is 
interesting that the E8pS mutant did not have a more dramatic increase in binding affinity.  We 
also attempted to generate a higher affinity peptide by recombining the highest affinity 
sequences from selection.  Although none of these attempts generated a higher affinity peptide, it 
is interesting to note that the point mutations had much less of an effect on binding that any 
attempts to recombine whole sections of the sequences.   
ITC analysis showed that AN 8.6 had a Kd of 1 µM making this the tightest non-
phosphorylated (BRCT)2 domain binder discovered to date.  The thermodynamic information 
from the ITC analysis raised more questions than it answered about the potential binding 
mechanism of these peptides.  Hopefully these questions can be answered with the 
crystallographic studies that are underway.   
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Comparison to current inhibitors. Our peptide may not be the tightest-binding molecules 
discovered to date that bind to the (BRCT)2 domain, but there is much more to drug design than 
affinity.  A molecule without a phosphate is arguably much more cell permeable and stable, 
which is a significant advance in the quest for an inhibitor of BRCA1.
79
  Small molecule screens 
have resulted in peptides in the mid-micromolar range, yet despite fewer drug delivery issues 
with small molecules they were unable to effectively inhibit BRCA1 function.
132
  With small 
molecules seemingly unable to do the job, many phosphopeptides have been tested that are 
higher affinity that the previous small molecules, and have been shown to inhibit (BRCT)2 
binding proteins in cell lysate.  Translation of these effects into cells has been much more of a 
challenge.  Even the highest affinity peptide required high (100 µM) concentration and had 
minimal inhibitory function.  The trade-off in the history of BRCA1 (BRCT)2 inhibition seems to 
have been presence of a phosphate or an inhibitor.  Our highest affinity peptide is not close to the 
40 nM affinity achieved with phosphopeptides, but how tight does the affinity need to be? 
 
Comparison to Native (BRCT)2 binding partners. In the development of inhibitors it is usually 
the goal to develop a molecule that will bind to the desired site with the tightest affinity possible.  
Affinity is important, but so is cell permeability and stability.  A lower affinity inhibitor may be 
more affective in the end depending on the system.  There are several known proteins that bind 
to the (BRCT)2 domain, and of these the  proteins BACH1 and CtIP currently have the highest 
affinity (see Table 5.5).  Several studies have been conducted reporting the binding affinity via 
ITC for these interactions.  For BACH1 reports have ranged from 0.9 to 0.17 µM and for CtIP 
reports are a bit higher ranging from 3.7 to 1.32 µM.  Thus our non-phosphorylated pepeptide is 
in the same range as the natural protein binders.  
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Table 5.5 Peptides Known to Bind to the (BRCT)2 Domain. This table is a list of peptides 
known to interact with a reasonably high affinity with the (BRCT)2 domain of BRCA1.     
Peptide Sequence Affinity (µM) Reference 
p-ACC1 DSPPQpSPTFPEAGH 5.2 
133
 
1 Ac-pSPTF-CONH2 2.51 
128b
 
CtIP PTRVpSPVFGAT 1.32-3.7 
134
 
7 Ac-pSPVF-CONH2 1.62 
128b
 
AN Peptide 8.6 MCTIDFDEYRFRKT 1.0 
 
BACH1 ISRSTpSPTFNKQ 0.17-0.9 
134a, 135
 
18 Ac-pSPTF-COOH 0.19 
128b
 
19 Ac-pSPVF-COOH 0.29 
128b
 
15 *pSPVF-COOH 0.04 48a 
* N-terminal constrained by a 3-carbon linker with a phenyl ring .
134, 135c
 These affinities are 
quite similar to the peptides discovered with this selection.  Although a higher affinity inhibitor 
is desirable, and will be a future direction for this work, given that the affinities of BACH1 and 
CtIP for this domain are in the low micromolar and high nanomolar range, our peptide will likely 
have a significant functional improvement with advancements in its current affinity.    
 
Functional Analysis of Peptide 8.6. Perhaps the most important result from these studies, is 
the initial demonstration that AN 8.6 can function as an inhibitor of BRCA1 (BRCT)2 
interactions in cell lysates in a dose dependent manner. Although this study does address 
protease resistance of the peptide due to the presence of protease inhibitors in the assay, it does 
lend support to the specificity of the inhibitor.  If non-specific binding were to be significant, 
much larger quantities of the peptide would be needed to inhibit the (BRCT)2-CtIP interaction.  
As it stands here the concentration needed to significantly inhibit the interaction approximates 
the Kd measured by ITC. 
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It is unlikely that we would have been able to find peptide 8.6 if we had made a library of 8 
randomized AAs since the N-terminus through AA F11 are required for binding.  However, the 
extreme diversity of our peptide libraries has allowed us to find tight-binding non-
phosphorylated inhibitors when other library approaches failed.  Given enough diversity, binders 
to challenging targets can be uncovered, including those previously requiring phosphoserine.   
 
5.8 Experimental 
Peptide synthesis. The peptides were synthesized using a Liberty Automated Microwave 
Peptide Synthesizer (CEM). The peptides were synthesized on Fmoc-PAL-PEG-PS Resin 
(Applied Biosystems) using N-α-Fmoc-protected amino acids (CEM or AAPPTEC) or unnatural 
N-α-Fmoc protected amino acids (Chem Impex). After each coupling step a capping step was 
performed using 20% acetic anhydride (Fisher Certified ACS). The peptides were cleaved from 
the resin using trifluoracetic acid (TFA) (Chem Impex)/TIS (Sigma)/DODT (Sigma)/water 
(92.5:2.5:2.5:2.5) with incubation at room temperature for 3 hours, and the resin was filtered off.  
The filtrate containing the crude peptides was precipitated with cold ether and collected by 
centrifugation.  The supernatant was discarded and the peptide was dissolved in CH3CN (Fisher 
HPLC Grade) and water with 10% acetic acid (Fisher certified ACS PLUS) (1:1) followed by 
freezing and lyophilization.  The peptides were then purified by reverse phase HPLC using a 
Shimadzu Prominence system with a Vydac (218TP C18 5μ) column with 0.1% TFA in water 
(A) and CH3CN (B) as the mobile phase with monitoring at 215nm or 264nm.  A typical gradient 
was 10-100% B over 30 minutes, but was adjusted for each peptide.  MS data was collected 
using a Micromass MALDI-R spectrometer. 
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Determination of Protein and Peptide Concentrations.  All protein and peptide concentrations 
were determined using their UV absorbance at 280 nm according to the method of Gill and von 
Hippel 
126
.  Extinction coefficients: GST-(BRCT)2 = 76810 M
-1
cm
-1
; TR-(BRCT)2 = 50070 M
-
1
cm
-1
; FAM = 75800 M
-1
cm
-1
; Peptides = 1280 M
-1
cm
-1
 (for peptides containing a single Tyr); 4-
F-Phe = 500 M
-1
cm
-1 
(for peptides with no Tyr, but contain at least one 4-F-Phe).  
Determination of IC50 with Fluorescence Polarization.  The indicated amounts of competing 
peptide were added to a total of 150 µL containing 2.5 µM TR-(BRCT)2 and 20 nM FAM-β-Ala-
pSPTF in 300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4.  The samples were incubated 
at room temperature for 2 hours.  The samples were then analyzed in a 100 µL quartz 
fluorescence cuvette using a Cary Eclipse Fluorescence Spectrophotometer (Varian Instruments) 
with polarizing lens attachment.  The G-factor was experimentally determined with sample 
containing 20 nM FAM-β-Ala-pSPTF in the same buffer.  Anisotropy values were automatically 
calculated by the accompanying Advance Reads software.   After plotting anisotropy versus 
peptide concentration, an IC50 was determined as the peptide concentration at which 50% of the 
FAM-β-Ala-pSPTF was bound by fitting to the four parameter logistic equation using SigmaPlot 
11.  
Isothermal Titration Calorimetry. ITC experiments were performed on an ITC-200 
calorimeter (Microcal Inc.) in 300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4.  
Experiments were carried out by titration of 200-400 µM peptide in the syringe into 20-30 µM 
TR-BRCT protein in the sample cell. The cell was thermostated at 25 °C and the syringe was 
stirred at 400 rpm. Each titration consisted of 20 injections of 2 µl except for the first addition 
which was only 0.5 µL.  This first data point was deleted prior to data analysis.  Control 
experiments consisted of titration of peptide into buffer alone to determine the heat of dilution 
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which was subtracted from the data collected from the peptide into protein titration.  The 
resulting data was fitted using a one-set binding-site model analysis using Origin 7 software 
(Microcal Inc.) to obtain binding stoichiometry (N), association constant (Ka), change in 
enthalpy (ΔH).  ΔG and ΔS were calculated with the following equations: ΔG = -RT*ln(Ka) and 
ΔS = (ΔH – ΔG)/T.   
Preparation of Cell Lysates. HEK293T cells were cultured at 37 °C in DMEM (Gibco) medium 
supplemented with 10% FBS and 1% pen-strep. The CtIP-myc expressing pcDNA3-5X vector 
was as described. 
117
  Five million 293T cells were transfected with 5 µg plasmid using an 
Amaxa Nucleofector II (Lonza) according to the manufacturer’s protocol (program A-023).  5-
days post-transfection, total cell lysates were prepared in 1.5 mL RIPA buffer (10mM Tris pH 7, 
1% Triton-X, 0.1% SDS, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 0.1% sodium 
deoxycholate) containing 1:100 dilutions of Phosphatase Inhibitor Cocktails 2 and 3 (Sigma) and 
1:100 dilution of Protease Inhibitor Cocktail for use with mammalian cell and tissue extracts 
(Sigma).  Cell lysates were used immediately for pull-down experiments. 
Pulldown-Western.  40 µL of the commercial Glutathione magnetic bead suspension (Pierce) 
were washed three times with 200 µL beads wash buffer (125 mM Tris-HCl pH 8, 150 mM 
NaCl).  To the washed beads, 200 µL of 250 nM GST-(BRCT)2 fusion protein was added and 
incubated while tumbling at 4 °C overnight. Beads were then washed three times with 300 mM 
NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4, and 100 µL of peptide solution in the same 
buffer was added.  The samples were incubated at 4 °C for 1.5 hours.  To these samples 100 µL 
of cell lysate was added and incubation continued for another hour.  The magnetic beads were 
washed three times with RIPA with inhibitors, and boiled for 10 minutes in 1x Laemmli buffer 
(BioRad) followed by separation on 10% SDS-PAGE in running buffer (25 mM Tris, 192 mM 
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glycine, 0.1% SDS) and Western blotting.    
Western Blot Analysis.  After separation by SDS-PAGE, proteins were transferred to a 
polyvinyl difluoride membrane (PVDF, 0.45 mm, Immobilon-FL, Millipore) by wet transfer at 
0.6A for 2 h with transfer buffer (25 mM Tris, 192 mM glycine). Subsequently, the PVDF 
membranes were blocked in blocking buffer (0.1X PBS and 0.1 % casein, BioRad) for 1 hour at 
room temperature with gentle agitation. The primary antibodies (mouse anti-myc, Cell Signaling; 
rabbit anti-GST, Cell Signaling) were diluted 1:1000 in blocking buffer and incubated overnight 
at 4 °C with gentle agitation. The blot was washed 3 x 15 min at room temperature with PBS-T 
(1X PBS, 0.2% Tween). Bound antibodies were labeled using secondary antibodies (Invitrogen 
goat anti-mouse AlexaFluor 680, Rockland goat anti-rabbit Dylight 800) in a concentration of 
1:2000 in blocking buffer. After incubation for 1 hour at room temperature, three further washing 
steps of 15 min each at room temperature in PBS-T followed.  The protein was imaged and 
quantified using the Odyssey Infrared Imaging System and application software version 3.0 (Li-
Cor Biosciences). 
 
5.9 Summary 
  None of the truncated version of peptide 8.6 that were tested had a binding affinity lower 
than that of the full length peptide 8.6.  This supports the hypothesis that none of the selected 
library members had a second cysteine in their sequences due to a preference for an extended 
linear conformation.  Mutational analysis supports the theory that the D/E-X-X-F motif is 
important for binding and perhaps binds in the same site as the known pS-X-X-F motif.  
Attempts to hybridize peptides 8.6 and 8.1 did not result in discovery of a higher affinity peptide, 
but did uncover multiple nearly neutral mutations.  In the end, the all-natural analog of peptide 
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8.6 (AN 8.6) proved to be the highest affinity peptide found with a Kd of 1 µM.  Initial in vitro 
inhibition of the (BRCT)2 domain CtIP in cell lysate appears to shows that AN 8.6 is the first 
good, non-phosphorylated inhibitor of BRCA1.   
 
Future Directions:  Cell studies with all-natural peptide 8.6 (AN 8.6) are needed to test its 
potential as an inhibitor of BRCA1.  Because this peptide uses natural amino acids it could be 
over expressed in a cell as an alternative to delivery with a cell penetrating peptide tag or other 
delivery means.  Although, initial in vitro studies show that AN 8.6 can inhibit protein-protein 
interactions of the (BRCT)2 domain, additional studies are needed to support the binding of this 
peptide in the same binding cleft.  Binding studies with protein mutations would be useful in 
demonstrating this.  A crystal structure of an 8.6 analog and the (BRCT)2 domain is also being 
pursued and will hopefully provide definitive evidence of how the peptide is binding to the 
protein surface.  This study has also served as a proof of principle for using large mRNA-display 
libraries for discovery of peptides that bind to a BRCT domain that is traditionally thought only 
to bind phosphopeptides.  This same technique could be applied to the many other BRCT 
domains as well as other targets to select inhibitors of other protein-protein interactions.   
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CHAPTER 6. OVERCOMING CURRENT LIMITATIONS: 
 
EXPANSION OF DRaCALA TO PEPTIDES 
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6.1 Introduction 
 The most difficult challenge faced in finding a non-phosphorylated peptide inhibitor of 
the BRCA1 (BRCT)2 domain was actually characterizing the peptides that were discovered in 
selection.  This experience highlighted the shortcomings of many of the standard binding affinity 
analysis techniques we use.  Although many of these techniques have great power, the more 
complicated a technique is the more prone to technical difficulties it becomes.  Work by the Lee 
lab produced a technique that has been named the differential radial capillary action of ligand 
assay (DRaCALA) which provides a very simple means of characterizing the binding affinity of 
DNA to protein based simply on their differential diffusion on nitrocellulose.
136
  Protein tends to 
bind non-specifically to nitrocellulose, and the high negative charge of DNA results in its 
diffusion across the membrane.  In the experiments conducted by the Lee lab, radiolabelled DNA 
in a constant concentration is mixed in samples with varying concentrations of an interacting 
protein.  After spotting only five microliters of each sample onto nitrocellulose, the amount of 
bound DNA can be ascertained from the diffusion pattern.  Any DNA bound to the protein will 
be observed as a darker inner circle, while unbound DNA is seen as a diffuse outer ring, as seen 
in Figure 6.1.  The fraction of DNA bound can be calculated be the equation 
   
       [       
(             )
               
]
      
    [6.1] 
where FB is the fraction bound, Vinner is the volume of the inner circle, Vouter is volume of the 
outer circle, Ainner is the area of the inner circle, and Aouter is the area of the outer circle.  
The simplicity of this technique has quite an appeal.  Not only does it not require 
expensive equipment that requires training and maintenance, but it also uses very small 
quantities of material for each assay.  The authors posit that this technique might be applied to  
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Figure 6.1 DRaCALA Experiment. In the proposed DRaCALA experiments, 
protein and fluorescent ligand are incubated together in a sample of small 
volume.  5 µL of this sample is spotted onto a dry, untreated sheet of 
nitrocellulose membrane. As the sample diffuses from the center spot, the 
protein interacts strongly with the nitrocellulose and remains in the center.  An 
ideal ligand for this interaction would diffuse uniformly with the solvent away 
from the center.  If the ligand binds to the protein an inner and outer circle will 
appear, as shown, upon visualization with a fluorescent scanner.  From analysis 
of this pattern a fraction bound can be calculated with Equation 6.1.  
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small molecules, but with its many advantages, we wondered if it could be applied to peptides.  
Nitrocellulose binds proteins which are chemically no different than peptides, except of course 
for their size.  It was hypothesized that there was likely some set of peptides that would have 
sufficient diffusion on nitrocellulose such that a DRaCALA assay could be used to study their 
binding affinity with proteins.   
 
6.2 Diffusion of Peptides on Nitrocellulose 
A set of test peptides was established to test for their ability to diffuse on nitrocellulose.  
These peptides were designed to test for different characteristics, including charge and length 
(Table 6.1).  Instead of using radiolabelled peptides, each peptide was fluorescently labelled with 
fluorescein as a means of detection.  Each set of peptides was dissolved at various concentrations 
in PBS and spotted onto nitrocellulose.  After drying, each was scanned at the appropriate 
wavelength to examine the diffusion pattern (Figure 6.2).  It was thought that perhaps the longer 
peptides would not readily diffuse on the nitrocellulose, but it was found that the approximately 
neutral peptides all displayed a central ring upon spotting which indicates they did not freely 
diffuse on nitrocellulose.  It was however, found, that the small and negatively charged pSPTF 
peptide did readily diffuse on nitrocellulose at all concentrations making it perhaps suitable for 
binding affinity analysis with this technique.   
 
6.3 Model Systems for Comparison to Current Techniques 
 After observing that BRCA1 peptide, FAM-β-A-pSPTF, could in fact diffuse readily 
across the nitrocellulose even at the highest concentration of 1 µM, it was tested in a binding  
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β-amyloid
pSPTF
18mer
Angio. II
Figure 6.2 Test of Peptide Diffusion on Nitrocellulose. The fluorescently labeled 
peptides indicated  (whose sequences can be found in Table 6.1) were spotted at 
the concentration indicated onto dry, untreated nitrocellulose and examined on a 
fluorescence scanner. Each spot is the result of 5 µL of sample. 
Conc, (nM) 1000      300     100        30        10          3         1
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study with the thioredoxin (TR) fusion of the (BRCT)2 domain. Solutions with 20nM of FAM-β-
A-pSPTF and concentrations of TR-(BRCT)2 ranging from 100-0.05 µM were incubated for two 
hours in buffer. The samples were spotted in six replicates due to irregularities in the samples 
shape and background interference in some samples.  These samples were analyzed on a 
fluorescence scanner, and the fraction bound for each circle was calculated.  The scanned sheet 
of nitrocellulose and the resulting binding curve from analysis is shown in Figure 6.3.  The Kd 
determined was 4.8 ± 0.1 µM.      
 
6.4 Discussion 
 Four peptides were spotted at concentrations ranging from 1000-1 nM, and were spotted 
on nitrocellulose.  After drying their diffusion patters were examined with a fluorescence 
scanner.  It is clearly shown in Figure 6.3 that the three longest peptides did not diffuse readily 
across the nitrocellulose even at the lowest concentrations test.  In each spot there is clearly 
visible both an inner and an outer ring.  The fourth and shortest peptide however, shows a single 
diffuse circle the same size as the outer ring for all the other peptides.  This was present at each 
concentration tested indicating this peptide is clearly diffusing even at the highest concentrations 
tested.  This makes the short, dense negatively charged FAM-β-A-pSPTF peptide potentially 
suitable for binding affinity analysis via DRaCALA.  
DRaCALA is an attractive alternative to FP and ITC in the measurement of the binding 
affinity of the FAM-β-A-pSPTF peptide. First, the small volume of the DRaCALA assay 
conserves significant amounts of material.  Second, and more importantly, the BRCA1 protein 
tends to aggregate at higher concentrations.  This aggregation leads to light scattering and 
prevents measurement of the upper bounds of the Kd by FP.    
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Replicate
1
2
3
4
5
6
TR-(BRCT2concentration (µM)
100    50    25   12.5   6.2    3.1   1.6    0.8    0.4   0.2    0.1   0.05
Figure 6.3 DRaCALA of 5-FAM-pSPTF. Analysis of a peptide known to bind to 
the BRCA1 (BRCT)2 domain, 5-FAM-pSPTF, was conducted by incubating the 
peptide at 20 nM and the TR-(BRCT)2 fusion protein for two hours. 5 µL of each 
sample was spotted in six replicates on nitrocellulose  A) The resulting spots 
analyzed by a fluorescent scanner.  B) The binding curve resulting from analysis 
of the spots shown in A.
A
B
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β-A-pSPTF labeled with FITC has previously been reported to bind to the (BRCT)2 
domain of BRCA1 with an affinity of 2.28 ± 0.09 µM.
48a
  Testing the affinity of FAM-β-A-
pSPTF to TR-(BRCT)2 with DRaCALA produced a binding affinity of 4.8 ± 0.1 µM, which is 
quite close to the previously reported value, suggesting that in this case DRaCALA is able to 
measure accurately the binding constant.  The difference of these values may owe more to the 
difference in attached fluorophore or the difference in protein used for the study.  It is of course 
difficult to draw general conclusions about this technique from a single study, however, this 
bodes well for future uses of this technique to measure the binding affinity of short, negatively 
charged petpides.   
 
6.5 Experimental 
Peptide synthesis. The fluorescently labelled β-amyloid, angiotensin II and 18 mer peptides 
were purchased from Anaspec, and no further purification was performed. The β-A-pSPTF 
peptide was synthesized using a Liberty Automated Microwave Peptide Synthesizer (CEM). The 
peptides were synthesized on Fmoc-PAL-PEG-PS Resin (Applied Biosystems) using N-α-Fmoc-
protected amino acids (CEM or AAPPTEC) or unnatural N-α-Fmoc protected amino acids 
(Chem Impex). After each coupling step a capping step was performed using 20% acetic 
anhydride (Fisher Certified ACS), but no capping was performed on the final N-terminal amino 
acid to leave the amine free for labelling. The peptide was cleaved from the resin using 
trifluoracetic acid (TFA) (Chem Impex)/TIS (Sigma)/DODT (Sigma)/water (92.5:2.5:2.5:2.5) 
with incubation at room temperature for 3 hours, and the resin was filtered off.  The filtrate 
containing the crude peptide was precipitated with cold ether, and collected by centrifugation.  
The supernatant was discarded and the peptide was dissolved in CH3CN (Fisher HPLC Grade) 
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and water with 10% acetic acid (Fisher certified ACS PLUS) (1:1) followed by freezing and 
lyophilization.  The peptide was then purified by reverse phase HPLC using a Shimadzu 
Prominence system with a Vydac (218TP C18 5μ) column with 0.1% TFA in water (A) and 
CH3CN (B) as the mobile phase with monitoring at 443 nm.   
Spotting Peptides on Nitrocellulose.  All peptides were dissolved in PBS (137 mM NaCl, 2.7 
mM KCl, 10 mM phosphate, pH 7.4) and diluted to the indicated concentrations.  5 µL was 
spotted of each was spotted onto dry-untreated nitrocellulose (Bio-Rad Trans Blot Transfer 
Medium) at least 2 cm apart.  Spots were allowed to dry for 20 minutes and scanned on a 
Typhoon 9410 Variable Mode Imager (Amersham Biosciences) with an excitation wavelength of 
488 nm.  Resulting images were analysed with ImageQuant 5.1 software. 
DRaCALA. Protein was mixed with 20 nM radiolabeled nucleotide in buffer (300 mM NaCl, 
2.7 mM KCl, 10 mM phosphate, pH 7.4) and allowed to incubate for 2 hours at room 
temperature. These mixtures were pipetted (5 μL) onto dry untreated nitrocellulose (BioRad 
Trans Blot Transfer Medium) at least 1 cm apart in six replicates and allowed to dry completely 
before scanning on a Typhoon 9410 Variable Mode Imager (Amersham Biosciences) with an 
excitation wavelength of 488 nm.  Resulting images were analysed with ImageQuant 5.1 
software. 
 
6.6 Summary 
 Four fluorescently labeled peptides were tested for their suitability for use as the ligand in 
a DRaCALA assay.  This was measured simply by spotting 5 µL of serially diluted peptide 
solutions onto nitrocellulose, and examining the pattern of diffusion on a fluorescence scanner.  
Only the shortest peptide, which also had the densest negative charge, freely diffused onto the 
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nitrocellulose.  This peptide was used in a DRaCALA assay to determine its binding affinity to 
the (BRCT)2 domain of BRCA1.  A value of 4.9 ± 0.1 µM was obtained, which is quite close to 
a previous literature report of 2.28 ± 0.09 µM.
48a
 This technique will not be generalizable to all 
peptides, but has shown here to work in special cases. 
 
Future Directions. Although this technique may not be applicable to all peptides, it did help us 
confirm the affinity of a peptide that was difficult to determine via other methods.  This might be 
a viable option for these special cases, but is not likely suited for hydrophobic and perhaps 
overall neutral peptides.  Preliminary data (not shown) indicates that larger negatively charged 
peptides diffuse readily on nitrocellulose, and that positively charged peptides like poly-arginine 
diffuse well on polyethyleneimine (PEI) membranes.  Additional study is required to confirm 
these conclusions.  
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Overall Summary and Conclusions 
 
 Inhibitors of the BRCA1 C-Terminal (BRCT)2 domain have been sought after, yet many 
of the traditional routes to drug discovery have failed to produce viable inhibitors.  Even 
successful attempts to design peptides that bind to the (BRCT)2 domain have been unable to 
produce a promising drug candidate due to reliance on the incorporation of a phosphoserine.  
Peptide libraries have previously proven themselves to be a powerful tools in selecting peptides 
that bind to protein surfaces, and an important aspect of this has been their large diversity which 
adds great power to these techniques.  Can this technique be used to overcome the phosphate 
“requirement?” We proposed that the large diversity (>1013 members) of an mRNA display 
library that does not contain phospho-amino acids could be applied to the selection of a non-
phsophorylated BRCA1 inhibitor.    
In addition to the large number of library members, unnatural amino acids (UNAAs) 
were also used in an attempt to increase the chemical diversity of the library.  This was 
accomplished via substation of some of the 20 naturally occurring amino acids with unnatural 
analogues.  This is possible because these libraries are constructed within a PURE translation 
system that allows for control of the in vitro translation reaction components.  By simply leaving 
out a natural amino acid, we can simply substitute a similar UNAAs that will be incorporated by 
the translation machinery instead.  Six UNAAs were found that work well together and were 
used in translation of the peptide library. 
The library peptides consisted of a fixed Met-Cys followed by a 12-amino acid random 
region encoded by an NNB codon (where N = A, C, T, or G and B = C, T, or G).  This decreases 
the number of stop codons, as well as enriches the number of cysteines found in the random 
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region so that 40% of the library members should have a second cysteine.  This is important as 
the library will be subject to cyclization with dibromoxylene that will act as a covalent linker 
selectively between two cysteines.   This will hopefully result in peptides with a more rigid 
peptide scaffolds that may lead to tighter peptide binding due to decreased entropic cost in 
binding. 
The selection was conducted over eight rounds against GST-(BRCT)2 fusion protein 
immobilized on magnetic glutathione beads.  In all but the first round, a pre-clearing step was 
conducted against immobilized GST. The selection enrichment was monitored via the 
35
S-Met 
incorporated in the peptides and calculated for each round.  In round 7 a spike in enrichment was 
observed followed by the beginning of a plateau in round 8.  The surviving peptides were 
sequenced and in the resulting sequences, seven peptides recurred more than once and comprised 
more than 80 % of the sequences.  These sequences were assigned numbers 8.1 to 8.7 based on 
their frequency in the sequencing results.  Each sequence contains a D/E-X-X-F motif, which is 
analogous to the pS-X-X-F motif known to bind the BRCA1 (BRCT)2 domain where the D and 
E are known phosphoserine mimetics.  This was a promising result indicating the peptide likely 
binds in known binding groove.  UNAAs that were selected were primarily the Phe analog (4-
fluoro-phe) and the Arg analog (canavanine).  It was interesting however, than none of the 
peptide sequences contained a second cysteine in the random region.  MS/MS analysis showed 
that the dibromoxylene is instead forming a sulfonium ion linkage with the fixed methionine.   
 An initial ranking of the 7 peptide families in both their linear and cyclized (treated with 
dibromoxylene) forms was achieved with a competitive fluorescence polarization (FP) study 
with a peptide (FITC-β-A-pSPTF) known to inhibit the (BRCT)2 domain.  However, these tests 
are not completely indicative of what was selected because one of the UNAAS, canavanine, was 
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unable to be incorporated in solid phase peptide synthesis, so arginine was substituted instead.  
Upon this initial ranking it was clear that linear peptide 8.6 (with the sequence 
MCTIDF26DEYRF26KRT) had the highest affinity with peptides 8.1 and 8.5 just behind with 
approximately two-fold lower affinity.   
 To further investigate how this non-phosphorylated peptide binds to the (BRCT)2 
domain, a series of truncated mutants were tested in the same FP assay.  The core domains 
(DEYRF26 and F26DEYRF26) were not sufficient to observe binding to the domain.  C-Terminal 
(MCTIDF26DERYF26) and N-terminal (DEYRF26RKT) deletions revealed that the contribution 
of the N-terminal amino acids are much more significant that the C-terminal amino acids due to 
over an order of magnitude decrease compared to the mere two-fold decrease in affinity observed 
with the C-terminal deletion.  Additionally deletion of the fixed MC at the N-terminus showed an 
approximately two-fold decrease affinity.  This seems to indicate that the full length peptide is 
necessary to achieve the highest binding affinity.   
 Further mutational studies were conducted to investigate the importance of individual 
amino acids in the sequence of peptide 8.6.  First, mutations of the E8 and F11 to A both nearly 
abolished binding altogether indicating that these amino acids are necessary, but not sufficient 
for binding.  The contrary mutation, replacing E8 with a pS, surprisingly had only a three-fold 
increase in binding affinity when previous pS to E mutations resulting in a multiple order of 
magnitude decrease in affinity.  Because of this observation, we wondered if the N-terminal 
amino acids would still be as important in the presence of the pS containing peptide.  This N-
terminal truncated pS peptide had a very slight increase in affinity leading to the conclusion that 
the N-terminal amino acids are no longer necessary when the pS is present in the E-X-X-F motif.  
Additionally, replacement of the two F26 amino acids with F resulted in a two-fold increase in 
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binding affinity.  The question of what role canavanine would play in these peptides is still open, 
but for now the all-natural (AN 8.6) will be used in future study. 
  One interesting variation between the 7 peptides found in selection is where the D/E-X-
X-F was positioned in the random region.  The two highest affinity hits 8.6 and 8.1 had very 
different position of this core motif.  With the core boing closer to the C-terminus in peptide 8.6 
and closer to the N-terminus in peptide 8.1, it was hypothesized that perhaps combining these 
sequences into longer peptides could result in a peptide that covers more of the protein surface 
and has a higher affinity.  However, after making three different hybrid combinations, none of 
these peptides had an affinity higher than peptide 8.6.  Mutations of individual amino acids of 
peptide 8.6 to amino acids found in the same position around the core domain of peptide 8.1 
were also investigated.  Although neither mutation of E8D, or Y9F and R10I achieved a peptide 
with a higher affinity than AN 8.6, they were less than a two-fold decrease in affinity.  The 
mutation of D7N was nearly a neutral mutation.   
 Isothermal titration calorimetry (ITC) was conducted on peptides 8.6, AN 8.6, 8.6 E8pS 
and 8.6 E8pS 8-14.  The affinities determined from ITC were found to be very similar to those 
determined by FP with AN 8.6 having a Kd of 1 µM.  No differences in binding mechanism 
could be determined, but each binding interaction was enthalpically driven.  
 Although these peptides seem to inhibit the (BRCT)2 domain in vitro, AN 8.6 was tested 
for its ability to inhibit binding interactions in cell lysate.  In a pull-down western experiment, 
binding of CtIP-myc in cell lysate was able to be inhibited from binding to immobilized GST-
(BRCT)2 fusion in a dose-dependent manner.  At concentrations of 50 µM in solution, this 
protein-protein interaction (PPI) was almost completely abrogated.   
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 This work has shown a means of developing a non-phosphorylated peptide that can 
inhibit a PPI that has been previously thought to be ‘un-druggable’ due to the “requirement” of a 
phosphate.  It has shown to be able to inhibit its target PPI in cell lysate, but there is still much 
work left to be done.  With a 1 µM affinity, it is unclear as to whether or not it will be a viable 
inhibitor in cells.  Preliminary data of cellular overexpression is promising, but can sufficient 
quantities of AN 8.6 be delivered exogenously?  Various cell-penetrating techniques can be 
applied, but such an effort would also be aided by an increased affinity peptide.  From this point, 
perhaps rational design would be a good place to start.  Preliminary crystal structure data has 
given us some information about how this peptide binds, but can this be peptide be optimized 
from this structural information?   
Another possibility is conducting another selection.  It was found that a linear 
conformation was preferred, and the current selection was limited to a 12 amino acid random 
region. Would a longer peptide be beneficial?  Throughout this work, it has been assumed that 
this peptide is in a floppy, linear conformation in solution, and remains linear upon binding, but 
what is its actual conformation in solution?  If there is helical propensity, is it possible that 
altering the sequence to change this propensity could increase the affinity? What about another 
selection with a semi-random region based on the crystal structure data?  Is optimization even 
necessary to begin to use this peptide as a tool?  With an all-natural amino acid sequence, it 
could be over-expressed in cells to study BRCA1 inhibition.  This work has also opened up the 
possibility of performing selections on other (BRCT)2 domains.  Each of these domains are 
known to interact with phosphoproteins, and in theory could be targeted with the same mRNA 
display library approach.  
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 There are many directions that this work could continue, and in the grand tradition of 
scientific investigation it has opened more questions that it has answered. However, it did answer 
some important questions.  We were able to use the power in numbers to find a non-phosphate 
containing inhibitor of BRCA1’s (BRCT)2 domain, and demonstrate that this inhibitor could be 
used successfully in cell lysate to disrupt a PPI.  As PPIs become increasingly viewed as viable 
drug targets, studies like this one may help pave the way for a new method of drug design.   
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Appendix I MALDI-TOF Analysis of Peptides 
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Appendix II Fluorescence Polarization Binding Curves 
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